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RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OFF-LABEL USE OF
ATYPICAL ANTIPSYCHOTICS IN AN ADULT POPULATION
By Della Varghese, PharmD, MS, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2016
Advisor: Norman V. Carroll, PhD
Professor, Department of Pharmacotherapy and Outcomes Science
Introduction: Atypical Antipsychotics (AAPs) are approved by the Food and Drug Administration
(FDA) for the treatment of schizophrenia and bipolar disorder. AAPs are commonly used off-label to
treat depression, post-traumatic stress disorder and neuropsychiatric symptoms in dementia due to lack
of alternative treatment options and treatment resistance. Concerns for off-label use arise since AAPs
increase the risk of cardiovascular events and death. The objectives were 1) describe patterns of RU
and costs among off-label AAPs users in a nationally representative population 2) identify prevalence
of off-label use in the Medicare population 3) compare RU and costs between off-label AAPs users
and non-users with mental health conditions in Medicare.
Methods: For the first objective, the Medical Expenditure Panel Survey (MEPS) datasets were used.
AAPs users greater than 18 years were identified in this cross-sectional study. Generalized Linear
Models (GLM) were used to estimate costs among users and non-users after controlling for age sex,
gender, insurance type, marriage status, income and comorbidity index. For the second and third
objective, Medicare datasets were used to identify prevalence, RU, and costs of off-label use in
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Medicare beneficiaries 18 years and older. RU and costs between propensity score matched AAPs user
and non-user cohorts were compared in a retrospective cohort study.
Results: The adjusted odds of having an office-based outpatient (OR=2.47, 95%CI: 1.55-3.92) or
inpatient (OR=1.63, 95%CI: 1.26-2.10) visit were significantly higher among off-label AAPs users.
Adjusted office-based visit ($1,943 vs. $1,346), prescription ($4,153 vs. $1,252) and total ($10,694 vs.
$4,823) costs were significantly higher among users (p<0.0001).
Among Medicare beneficiaries, approximately 37% of AAPs users had no FDA approved diagnosis.
The typical off-label user was a white 70-year-old male. Common off-label uses were depression,
anxiety and neurotic disorders and dementia. Off-label AAPs users had significantly higher mental
health outpatient ($461 vs $297), prescription ($2,349 vs $282) and total ($3,665 vs $1,297) costs per
beneficiary than non-users. About 30% of AAPs users had at least one mental health outpatient visit
during the year versus 23% of non-users; no significant differences were found in inpatient visits.
AAPs non-users had significantly higher all-cause inpatient costs ($6,945 vs. $4,841) per beneficiary
(p<0.0001) but there were no differences in total costs.
Conclusion: In a nationally representative population comprising a younger age group AAPs users
had higher all-cause RU and total costs than non-users. Off-label prescribing of AAPs continued to be
a prevalent practice affecting 37% of Medicare AAPs users. Off-label AAPs users had higher mental
health costs but no significant differences in all-cause total health care costs in a Medicare population.
Off-label use of AAPs can be a cost-effective option if future research shows off-label use is associated
with increased effectiveness, which offsets any additional costs.

Chapter 1: Introduction and Background
1.1 Introduction
Atypical antipsychotics (AAPs) have become the mainstay of treatment for a number of
mental health disorders. Even though the Food and Drug Administration (FDA) has approved most
AAPs only for the treatment of schizophrenia and bipolar disorder these drugs are used for other
mental health conditions such as depression, dementia and post-traumatic stress disorder (PTSD)
(Maglione et al., 2011). AAPs are now under increasing scrutiny for their increased “off-label”
use which the FDA defines as, "Use for indication, dosage form, dose regimen, population or other
use parameter not mentioned in the approved labeling.” Studies have shown that off-label
prescribing is a common phenomenon in outpatient care and off-label use of AAPs is prevalent in
different settings and conditions (Leslie et al, 2009; Alexander et al., 2011; Kamble et al., 2010).
In 2011, the Agency for Healthcare Research and Quality (AHRQ) released a review that
concluded that most off-label use of AAPs was not supported by moderate to strong evidence but
at the same time highlighted that not all off-label prescribing may lead to adverse effects (Maglione
et al., 2011). Concern for off-label use of AAPs arise from their propensity to cause metabolic and
cardiac adverse effects (McIntyre et al., 2001; Chung & Murray, 2009). Steps, such as a FDA
black box warning and Centers for Medicare and Medicaid Services (CMS) initiated partnerships,
have been implemented to decrease off-label use of AAPs specifically in the elderly.
On the other hand, even though there is concern regarding the use of these agents,
especially in vulnerable populations, the lack of alternative treatments and treatment resistance
have paved the way for off-label use among patients with depression, dementia and anxiety
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(Trivedi et al. 2006; Ravizza et al., 1995; Erzegovesi et al., 2001). Previous studies have shown
that initiation of off-label use of AAPs in patients with mental health conditions has led to
decreased hospitalization costs and decreased resource utilization (RU) from pre to post treatment
since these patients were not seeking treatment for emergent care (Del-Paggio et al., 2002; Lage.&
Rajagopalan,2006; Al-Zakwani, 2003). The main limitation of these studies was that they focused
only on a young population primarily with private insurance. The estimates from these studies are
also not nationally representative and do not focus solely on off-label use of AAPs.
This study aims to fill the gap in the literature by providing RU patterns and cost estimates
among off-label AAPs users in a community dwelling population using nationally representative
data. Secondly, this study also aims to compare RU and costs among AAPs users and non-users
from a public payer perspective in a population that largely comprises older adults.
The specific aims and background are provided in the remainder of this chapter. Chapter 2 explores
the literature that has assessed off-label use of AAPs and its effects on RU and costs. Chapter 3
presents the methods, results and discussion of a pilot study evaluating national patterns of
inpatient, outpatient and emergency visits among off-label AAPs users and non-users in a
community dwelling population of AAPs users and non-users. Chapters 4, 5 and 6 address the
methods, results and discussion of a study comparing the RU and costs among AAPs users and
non-users in the Medicare population.
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1.2 Specific Aims
Specific Aim I:
A: Examine RU pattern and estimate costs among off-label AAPs users and non-users in
a nationally representative sample
Specific Aim II:
A: Evaluate the prevalence of off-label and on-label use of AAPs and describe patient
characteristics in a Medicare population.

Specific Aim III:
A: Compare all-cause RU and costs between Medicare beneficiaries using AAPs
and those not using AAPs for off-label treatment of mental health conditions.
B: Compare mental health RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for off-label treatment of mental health conditions.
Specific Aim IV:
A: Compare all-cause RU and costs between Medicare beneficiaries using AAPs
and those not using AAPs for on-label treatment of mental health conditions.
B: Compare mental health RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for on-label treatment of mental health conditions.
Specific Aim V:
A: Evaluate differences in RU and associated costs in Medicare beneficiaries using AAPs
and those not using AAPs to treat specific mental health conditions.
.
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1.3 Background
Pharmacology

Antipsychotic medications have become the mainstay of treatment for a wide variety of
psychiatric conditions. Second generation antipsychotics or AAPs have become increasingly
popular as compared to first generation antipsychotics due to their better adverse effect profiles
(Harrison et al., 2012) and because of their effectiveness in adults (Duggan et al., 2003;
Srisurpanont et al., 2004; El-Sayeh et al., 2004; Bagnall et al., 2000; Hunter et al., 2003; Davis et
al., 2003). They are one of the most widely used classes of drugs with sales exceeding $14 billion
in 2008 and were the top selling drug class in United States in 2008 (Kuehn, 2010). The older
generation of antipsychotics or the typical antipsychotics are well known for their propensity to
cause undesirable side effects, primarily extrapyramidal symptoms (EPS), tardive dyskinesia and
increased prolactin levels (Gardner et al., 2005). The undesirability of these effects and
irreversibility of certain adverse effects have led to a rapid increase in the use of AAPs over the
past years.
This class of drugs work by acting at the dopamine receptors. There are different kinds of
dopamine receptors that are responsible for a variety of neurological processes. Broadly, the fivedopamine receptors are D1-D5. The D2 receptor is the site of action for antipsychotics (Mauri et
al., 2014). Antipsychotics work by blocking the D2 receptor but unlike the first generation
antipsychotics, the AAPs rapidly dissociate from the D2 receptors therefore leading to lower EPS.
AAPs also act at certain serotonin receptors and this differential affinity for the different receptors
makes the individual AAPs unique from each other. For example, AAPs ziprasidone and
risperidone have high selectivity for both serotonin 5HT2A and D2 receptors, olanzapine and
4

quetiapine have affinity for 5HT2A and D2 receptors in addition to other receptors that are
cholinergic, histaminergic, and 5HT1A, and aripiprazole is a partial dopamine receptor agonist.
Pattern of use
AAPs medications have become the mainstay of treatment for a wide variety of psychiatric
conditions. There was a rapid increase in their utilization due to low propensity to cause EPS and
other movement related adverse effects. Even though these agents were originally approved for
the treatment of schizophrenia and bipolar disorder, they are widely used in the treatment of other
mental health conditions such as depression, dementia in elderly and others (Maglione et al., 2011).
Bipolar disorder: AAPs are the main treatment modality for bipolar disorder, either as
monotherapy or in combination with mood stabilizers. Almost 96.2% of patients who newly
initiated AAPs were using it as a monotherapy (Chen et al., 2013). Quetiapine, olanzapine and
risperidone were the most commonly used AAPs for the treatment of bipolar from 2002 to 2008
among patients newly initiating AAPs (Chen et al., 2013).
Depression: Data from the National Ambulatory Medical Care Survey (NAMCS) showed
that the rate of AAPs use increased from 4.6% in 1999-2000 to 12.5% in 2009-2010. The odds of
using AAPs to treat depression were 2.78 times higher in 2010 compared to 1999 (Gerhard et al.,
2013). Gerhard et al. report that even though some AAPs are approved by the FDA as adjunctive
treatment for depression in combination with antidepressants, there is a growing use of AAPs for
non-psychotic depression in the absence of antidepressant therapy.
Dementia: The non-cognitive symptoms of dementia such as aggression and agitation were
commonly treated using antipsychotics. In the early 1990s, there was a shift from using the typical
antipsychotics to the AAPs for the treatment of these symptoms due to their better side effect
5

profile (Lopez et al., 2003). But in the 2000s concern developed over the propensity of AAPs to
cause diabetes (ADA, 2004) and cerebrovascular effects (Brodarty et al., 2003; Wooltorton ,
2002). As a result, the FDA released a black box warning in 2005: “Treatment of behavioral
disorders in elderly patients with dementia with AAPs medications is associated with increased
mortality”. According to a study by Kales et al. which used national Veterans Affairs data, 10.72%
of patients with dementia were being prescribed AAPs in 1999, and the use increased to 14.4% in
2003 but then declined to 14.15% in 2005 post the black box warning (Kales, 2011).
Anxiety: Due to the sedative property of AAPs these drugs have also been considered
antineurotic and hypnotic medications (Linden & Thiels, 2001). AAPs use for anxiety increased
from 3.8% in 1996 to 20.5% in 2007 according to a study conducted on NAMCS (Comer et al.,
2011). During the same duration, use of typical antipsychotics decreased from 5.8% to 1.0%
(Comer et al., 2011). Interestingly, even though AAPs use sharply increased (OR=3.34, p<0.0001)
during the 12-year time frame, there was only a small increase in the use of FDA approved
sedative/hypnotics (OR=1.52, p<0.0001).
Post-traumatic stress disorder (PTSD): Even though AAPs are still being used in the
treatment of PTSD despite the availability of FDA approved first line treatments, the use showed
a declining trend from 2002 to 2009 (Bernardy et al., 2012). The overall frequency of use had
increased from 13.8% to 17.8% in 1999-2002 but declined to 10.4% in 2009 among veterans.
Safety concerns with AAPs use

Even though AAPs have a better side effect profile in terms of EPS and other movement
related disorders, other safety concerns that have risen over the last few years. According to a
national study that used Healthcare Cost and Utilization Project (HCUP) 2008 data, psychotropic
6

agents were in the top 5 classes of drugs that led to treat-and-release emergency department visits
and in the top 10 classes that led to inpatient stays due to medication related adverse event (Lucado
et al., 2011). Evidence from adult studies suggests that AAPs are linked with metabolic
disturbances; most commonly weight gain, hyperglycemia, diabetes, and hyperlipidemia
(McIntyre et al., 2001), stroke and cardiac deaths (Chung & Murray, 2009). In this section, the
adverse effect profile and reasons for safety concerns with AAPs use are explored in detail.
Metabolic concerns: AAPs have received a lot of attention over the last decade for their
propensity to cause a myriad of metabolic effects including weight gain, development of Type 2
diabetes and dyslipidemia.
-

Weight gain: The weight gain associated with AAPs use typically occurs within the first 12
weeks of initiation of treatment and is believed to be linked with the affinity of the molecule
to the 5HT2 receptor (Tschoner, 2007). Since olanzapine has the highest affinity for the
receptor, it is also the agent with the highest weight gain profile (Reynolds & Kirk, 2010).
Patients using olanzapine gained up to 4.15 kg in 10 weeks (Allison et al., 1999). Even though
olanzapine users had the highest weight gain, quetiapine and risperidone users have also been
shown to gain weight but ziprasidone users experienced weight loss in a trial (Lieberman et
al., 2005).

-

Type 2 diabetes: Due to the propensity to cause maximum weight gain, olanzapine also is also
associated with an increased risk for treatment-induced type 2 diabetes (Deberdt et al., 2005;
Newcomer, 2005; Lieberman et al., 2005). Patients developed signs of hyperglycemia as early
as within 6 weeks of initiation with AAPs (Tschoner, 2007) and 7% of AAPs patients were
diagnosed with diabetes at the end of one year in a veteran population (Leslie &
Rosenheck2004).
7

-

Dyslipidemia: Olanzapine was also associated with increased risk of dyslipidemia (Deberdt,
et al., 2005; Newcomer, 2005; Chaggar, 2010). In a double blind clinical trial patients had an
increase of 12.3 mg/dL total cholesterol levels after 8 weeks of olanzapine (Lindenmayer et
al., 2003).
In addition to the metabolic effects in all AAPs users, AAPs are known to be associated with

other adverse effects that affect the elderly in particular.
Risk of Death: In 2005, the FDA released a public health advisory based on a meta-analysis of
17 studies of four drugs (aripiprazole, olanzapine, quetiapine, and risperidone). The meta-analysis
showed that these studies, which cumulatively enrolled 5,106 elderly patients with dementia,
showed a 1.6-1.7 fold increase in mortality among AAP users versus non-users (Schneider et al.,
2005). Other studies have reported similar results wherein AAPs users were associated with higher
rates of mortality as compared to patients using other psychotropic medications and the risk was
seen to last over 6-12 months (Kales et al. 2007; Gill et al. 2007; Ray et al., 2009).
Cerebrovascular Risk: A meta-analysis by Hermann et al. combined the results from 11 trials
including 11,400 people over the age of 65 who were using risperidone, olanzapine or typical
antipsychotics. The study showed that that there was an increased risk of cerebrovascular adverse
events when compared to placebo (Herrmann & Lanctot, 2005). Similar results were reported by
Douglas et al. There is an increased risk of stroke in patients receiving AAP versus typical agents
(Douglas & Smeeth, 2008). Other studies reported similar risk of stroke among typical and atypical
users especially in patients with dementia (Gill et al. 2005; Liperoti et al. 2005; Shin, 2013).
Cardiac Risk: A recent study by Pariente et al. showed that concurrent antipsychotic (both
typical and atypical) and cholinesterase inhibitor use led to increased risk of myocardial infarction

8

within 30 days of use, but the risk significantly decreased after 30 days (Pariente et al. 2012).
Ziprasidone is also known to induce QTc prolongation that can increase the risk of torsade de
pointes (Glassman & Bigger, 2001).
Nephrological Risk: According to a new study AAPs can also cause acute kidney injury (AKI)
in adults aged 65 years and older which could lead to hospitalizations (Hwang et al., 2014).
Other Risks: Use of certain AAPs in patients with Parkinson’s disease is associated with an
increased risk of falls and fractures among the elderly. It was found that quetiapine (AOR=2.4),
risperidone (AOR=1.2) and olanzapine (AOR=1.7) were associated with higher rates of fracture
(Dore et al., 2009). Bauer et al. also reported that clinical characteristics such as diabetes,
hyperlipidemia, obesity, and overall cardiovascular risk were associated with use of AAP agents
in patients with PTSD (P<0.0001) (Bauer et al. 2014). Studies have also found that elderly AAPs
users have significant risk to develop pneumonia (Trifiro et al., 2010; Star et al., 2010) and deep
venous thromboembolism (Liperoti et al., 2005).
Due to these safety concerns, in 2005, FDA required all manufacturers of AAPs to include a
black box warning on their product label to warn patients about “an increased mortality in elderly
patients with dementia-related psychoses”. In 2012, the CMS initiated partnerships with multiple
stakeholders to decrease the off-label usage of AAPs among nursing home residents (Mort et al.,
2014).
Off-label Use
The Food and Drug Administration (FDA) defines off-label use as, "Use for indication,
dosage form, dose regimen, population or other use parameter not mentioned in the approved
labeling." Radley et al. showed that off-label prescribing is a common phenomenon in outpatient
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care and antipsychotics were among the top five classes of drugs for off-label use (Radley et al.,
2006).
Even though off-label prescribing is not illegal, off-label promotion of drugs by
manufacturers is. This is in order to prevent drug companies from trying to promote the use of
drugs for non-FDA approved indications. A number of lawsuits were filed against drug
manufacturers including Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis and AstraZeneca within
the past several years for same (Field, 2010). Majority of the litigation was based on claims that
the manufacturers promoted the use of AAPs in the elderly population even though the drugs were
only FDA approved for use in adult patients 18 to 65 years with schizophrenia or bipolar disorder.
Negative publicity over these large settlements has bought the off-label use of AAPs to the
forefront.
In 2011, the Agency for Healthcare Research and Quality (AHRQ) published a systematic
review of approximately 170 studies and concluded that the most common off-label uses of these
drugs were for anxiety, dementia in elderly patients, depression, and post-traumatic stress disorder
(PTSD) (Maglione et al. 2011). Other studies have shown that 60.2% of veterans in 2007, 66% of
outpatient AAPs users in 2008, and 20.3% of nursing home residents in 2004 used AAPs for offlabel conditions (Leslie et al, 2009; Alexander et al., 2011; Kamble et al., 2010).
Reasons for Off-label Use

Despite safety concerns, AAPs continue to be used in the treatment of a spectrum of mental
health conditions and the driving reasons behind this practice are a lack of alternative treatments
and treatment resistance for many mental health conditions (Tabarrok, 2000).
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Depression: Current practice guidelines state that patients with depressive disorders should
be treated using antidepressants (selective serotonin reuptake inhibitors (SSRI), serotoninnorepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor (MAOI)) in addition to
psychotherapy (APA, 2010). AAPs should be reserved for patients with severe depression with
psychotic features. Despite the availability of FDA approved first-line therapy AAPs continue to
be used as adjunct and monotherapy since 30-40% of depressed patients do not receive any
significant relief of signs and symptoms after two attempts of antidepressant therapy (Thase et al.,
1998). The STAR*D study reported that only one third of depressed patients had remission after
a vigorous initial trial of a SSRI (Trivedi et al. 2006). Treatment resistant patients had significantly
higher health care costs and utilization (Lepine et al., 2012). AAPs have shown to be effective as
adjunctive treatment for depression (Mahmoud et al. 2007).
Dementia: Current treatment guidelines state that cholinesterase inhibitors should be
initiated in patients with mild to moderate dementia (APA, 2014). There are no FDA approved
treatments for psychotic symptoms. AAPs have been shown to have some effect in decreasing the
psychotic symptoms associated with personality disorders and neuropsychiatric symptoms of
dementia (NPSD), neither of which have FDA approved first line treatments (Maher et al. 2011;
Rosenbluth & Sinyor, 2012). There is an increasing need for pharmacologic interventions to treat
NPSD in the presence of the rapidly aging baby boomer generation (Maher et al. 2011).
Anxiety and other neurotic disorders: In addition to psychotherapy, the FDA approved
certain antidepressants and benzodiazepines for the first line treatment of generalized anxiety,
panic disorders, phobias and obsessive-compulsive disorder (OCD). Even though 50-60% of
patients with anxiety respond to their treatment, only one-third to one-half attain full recovery
during the acute phase (Rickels et al., 2006) similar to 40-60% patients with OCD who failed to
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respond adequately to treatment with SSRI (Ravizza et al., 1995; Erzegovesi et al., 2001). A
systematic review suggested that there was some efficacy in using AAPs as augmentation therapy
in patients with treatment refractory anxiety though the report highlighted the need for more
rigorous studies (Lorenz et al., 2010).
PTSD: Current guidelines recommend the use of antidepressants such as sertraline and
paroxetine for the first-line treatment of PTSD. AAPs are effective as adjunctive treatment for
PTSD (Hamner et al., 2003; Petty et al. 2001; Sokolski et al., 2003; Stein et al., 2002), particularly
in presence of psychotic symptoms (Ahearn et al., 2003). Current treatment guidelines therefore
recommend the off-label use of AAPs only as adjunctive therapy in patients who have partially
responded to SSRIs and have psychotic symptoms (APA, 2009).
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1.4 Rationale
With increasing need and limited resources, it has become imperative to assess appropriate use
of health care resources and to identify areas of overuse. In psychiatry, AAPs are the cornerstone
of mental health pharmacotherapy. Even though AAPs are primarily approved for schizophrenia
and bipolar disorder, there is evidence for efficacy as well as evidence for adverse effects in
treating indications that are not approved by the FDA such as dementia and depression. Due to the
varying level of evidence, practitioners have little guidance as to when to prescribe AAPs for offlabel treatment and payers, such as CMS, have little information about the impact of using these
medications in the off-label treatment of mental health conditions on health care resources.
The aim of this descriptive study was to estimate the costs and RU associated with using AAPs
in the off-label treatment of mental health conditions. The results can help inform public policy
and assist health care professionals in designing health care guidelines targeting specific high-risk
mental health conditions.
Our study aims to describe treatment patterns and examine costs during 2008-2010. The CMS
initiatives to decrease AAPs use have been implemented since 2012 (Mort et al., 2014). Going
forward, the results of this study will provide baseline RU and costs associated with off-label use
of AAPs before the regulatory changes were implemented. This will enable us to evaluate the
changes in treatment patterns, RU and costs after the regulatory changes.
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Chapter 2: Literature Review
2.1 Summary of Literature on RU and costs of off-label AAPs Use
A review of the existing body of literature conducted using PubMed/MEDLINE and CINAHL
used the following search terms: (“Antipsychotic Agents” [Mesh] OR “Atypical Antipsychotics”)
AND (“Adult” [Mesh]) AND (“Mental Health Services” [Mesh] OR “Resource Utilization” OR
“Health Care Service”). The following inclusion and exclusion criteria were applied after
screening through the titles and abstracts:
Inclusion criteria:
1. Evaluates health care RU by patients using AAPs for off-label treatment.
Exclusion criteria:
1. Only evaluates RU in patients using AAPs to treat schizophrenia or bipolar disorder.
2. Studies that are not conducted in the United States.
3. Studies that assess RU in a pediatric population.
The search in PubMed and CINAHL initially yielded 431 articles. After screening titles and
abstracts, removing duplicate articles and applying the inclusion and exclusion criteria, two studies
were extracted for final review. The references of these two studies were reviewed to evaluate if
any other studies met the inclusion criteria but were missed during the literature search but no
additional articles were found from the references. Upon reviewing articles on Google Scholar,
one more article was found which was not available on the databases.
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Table 1: Articles included in the summary of literature
Author

Comparators Mental health
conditions

Data source

Outcome

Findings

Lage et al.
(2005)

-Olanzapine
-Quetiapine
-Risperidone

-Schizophrenia
-Bipolar disorder
-Dementia
-Depression

-MarketScan
commercial claims

-Hospitalizations
-Emergency visits

-Olanzapine and risperidone
users had higher rates of
hospitalizations and ED visits
from baseline to EOS
-Quetiapine users had lower
number of hospitalizations and
ED visits from baseline to EOS

Al-Zakwani et al. -Olanzapine
(2003)
-Quetiapine
-Risperidone
-Clozapine

-All mental health
conditions
(ICD-9-CM: 290319)

-Private claims
data from a health
plan

-Outpatient visits
-Hospital admissions
-Hospital outpatient
visits
-Emergency visits

-AAPs users were compared to
typical antipsychotic users and
AAPs users experienced fewer
office visits, hospital admissions,
and ED visits compared to
typical antipsychotic users

Del Paggio et al.
(2002)

-Thought
disorders
-Other disorders
(bipolar disorder,
depressive
disorder, OCD,
PTSD)

-Large county
operated mental
health care system

-Hospital costs
-ED costs
-Medication costs
-Outpatient costs

-Patients had significantly
decreased hospital costs, and ED
costs in the 12 month follow up
period from baseline
-Medications costs and
outpatient costs increased in the
olanzapine users from baseline
to EOS

-Olanzapine

*AAPs: Atypical antipsychotics, OCD: Obsessive-compulsive disorder, PTSD: Post-traumatic stress disorder, ED: Emergency department, EOS:
End Of Study
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Summary

Lage et al. (2006)

Lage et al. conducted a retrospective study using a large claims database to evaluate
differences in hospitalizations and emergency department visits among patients with mental illness
who were initialized on different AAPs. The study utilized the MedStat MarketScan Commercial
Claims and Encounters (CCE) database (Thomson MedStat). The database includes health related
data from approximately 100 payers. The dataset contains information on health care utilization
(inpatient, outpatient, prescription drug and carve-out services) and the associated expenditures.
Only patients newly initiated on olanzapine, quetiapine or risperidone between July 1, 1998
and July 2, 2002 were included in the study. The index date was the date of first antipsychotic
prescription fill. All included subjects had continuous enrollment for the six months before and
after the index date. The outcomes of interest were the differences in rates of inpatient
hospitalizations and emergency department (ED) visits between the pre and post index date
periods.
Of the 23,778 patients that met the inclusion criteria, 8,730 received olanzapine, 5,709
received quetiapine and 9,339 received risperidone mostly for schizophrenia, bipolar disorder,
dementia or depression. The results indicate that for all three antipsychotic drugs, there were
significant differences in the outcomes between the pre and post period. Patients initiated on
olanzapine and risperidone had significantly higher RU in the post period as compared to the pre
period. Olanzapine users had higher rates of hospitalization (2.47% higher), higher ED visit rates
(3.87%) and an increase in the mean number of hospitalizations by 0.13. Similarly, risperidone
users had 1.71% and 4.69% more hospitalizations and ED visits respectively and an increase in
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the mean number of hospitalizations by 0.12. On the other hand, quetiapine users showed
significantly reduced RU with a 4.37% decrease in hospitalizations and 2.98% reduction in ED
visits. Upon comparing across the three cohorts of patients who were treated with olanzapine,
quetiapine or risperidone after controlling for age, gender, region and mental illness diagnosis,
quetiapine users had significantly lower RU after initiation of therapy. Patients initiated on
risperidone were also younger and more likely to be male as compared to olanzapine and
quetiapine users. There were also significant differences among the cohorts with respect to mental
health diagnoses, olanzapine users were more likely to have bipolar disorder and quetiapine users
were less likely to be depressed.
The results of this study indicated that there were differences in the measured RU
(hospitalizations and ED visits) when comparing the periods before and after initiation of AAPs.
The results from this study did not provide conclusive evidence of whether initiation of AAPs
increased or decreased RU among patients since the results varied by the drug used. Patients who
initiated quetiapine experienced significantly lower RU after initiation but patients using
olanzapine and risperidone had higher RU in the post initiation period. Since ED visits and
hospitalizations can drive up the health care costs, the authors point out the importance of
identifying therapies that can assist in decreasing the costs and improving patient outcomes. In
previous studies Leal et al. and Dickson et al. reported lower RU after treatment with risperidone
in patients with schizophrenia (Leal et al., 2004; Dickson et al., 1999) but the study by Lage et al.
had also included patients with depression and dementia, neither of which is approved to be treated
with AAPs.
One of the main limitations of the study was the lack of generalizability of the results. The
study sample comprised privately insured patients while a large proportion of the population who
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are diagnosed with mental health conditions have public insurance either via Medicaid or via
Medicare. The sample also comprised young cohorts of patients with mean age from 37 to 40
years, therefore the results cannot be extrapolated to an older population who are most vulnerable
to the adverse effects of AAPs. Other limitations include the inability of the study to capture
outcomes such as quality of life and functional status of patients due to the nature of the data and
only evaluating hospitalizations and ED visits as RU.

Al-Zakwani et al. (2003)

Al-Zakwani et al. conducted a study to examine the effects of both atypical and typical
antipsychotics on healthcare RU. For the study, reimbursement data from a private health plan was
used which contained information on approximately 500,000 beneficiaries. Only patients between
six and 65 years of age who had newly initiated an antipsychotic agent between July 1, 1999 and
September 30, 2000 were included in the study. The date of the first antipsychotic prescription fill
was the index prescription date (IPD). Only patients who were continuously enrolled in the health
plan for six months before and 12 months after the IPD were included in the study. Patients were
categorized as the atypical drug cohort or the typical drug cohort. One of the outcomes of interest
was RU, which was measured as the number of office-based outpatient, hospital inpatient and
outpatient, emergency room, and mental health visits. All mental health diagnoses were included
in the study.
A total of 469 patients were included in the study of which 82% were AAPs users and only
18% were using typical antipsychotics. Majority of the patients were using the medications to treat
some form of psychosis (79%) and neurosis (42%). Some of the other main mental health
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conditions included drug and alcohol dependence, depressive disorders, and mental disorders of
childhood origin.
As compared to the typical drug class users, AAPs users experienced 45% fewer office
visits, 76% fewer hospital admissions, 41% fewer hospital outpatient visits and 67% fewer
emergency room visits after controlling for age, gender, medication possession ratio (MPR), length
of therapy, treatment augmentation and switches. The mean age of the AAPs users was only 34
years and almost 75% were prescribed concomitant antidepressants.
The result of this study indicate AAPs users have lower hospital admission rates and office-based
outpatient and emergency visits over the one-year period after initiation of AAPs compared to
typical antipsychotic users. The major strength of this study is that it assessed RU among all mental
health disorders and did not exclude patients who were using AAPs for off-label treatment. The
authors also note that AAPs users had higher rates of concomitant psychotropic drug use such as
antidepressants and mood stabilizers and this association could drive down the rates of RU.
As with the study by Lage et al. this study used data from a private health insurance plan
therefore the results are only generalizable to a population comprising private health plan
beneficiaries and not to patients who have public insurance. Another major limitation is that the
study explicitly stated that patients over 65 years were not included in the study. Therefore, even
though this study assessed RU among off-label AAPs users, the results cannot be extrapolated to
an elderly population who are more prone to the adverse effects of AAPs. The authors note other
limitations due to the retrospective nature of the study and secondary database. Confounding due
to unobserved factors such as physician’s justification for selection of different therapies and
selection bias are also limitations to the study.
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Del Paggio et al. (2002)
Del Paggio et al. conducted a study within the Alameda County Behavioral HealthCare
Services (BHCS) which is a non-profit organization located in California. The BHCS serves
approximately 1.4 million residents, provides community-based treatment for the severely
mentally ill patients, and covers all services such as inpatient hospitalization, emergency
services, residential treatment, outpatient services and medications. All outpatients who received
coverage by BHCS and began olanzapine treatment between November 1, 1996 and April 30,
1998 were included in the study. Economic and RU data were collected from the Insyst database
(countywide system maintained by BHCS) and the Pharmaceutical Care Network’s
MedIntelligence Access Database (a pharmaceutical benefits management company that was
contracted to automate the pharmacy providers within the county network). The date of the first
olanzapine fill was the index date and only patients continuously enrolled 12 months before and
after the index date were included in the study.
One hundred and eighty nine patients were identified in the BHCS system who had been
initiated on olanzapine during the study period. The mean age of the patients was approximately
36 years reflective of a younger population. Majority of the patients (66%) had diagnosis for
thought disorders whereas the other 34% comprised patients with bipolar disorder, depressive
disorder, obsessive-compulsive disorder, adjustment reactions and post-traumatic stress disorder.
Of the 189 patients, 78 continued olanzapine therapy for 12 months or switched to another agent.
These patients had significantly decreased hospital, and emergency costs in the 12 month follow
up period. There was a mean decrease of $4,423 per patient in hospital costs and $203 per patient
in emergency costs from before the index date to after the index date. On the other hand,
medications costs significantly increased by $1,585 per patient. Even though the individual
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components showed significant changes, the overall RU difference was non-significant with a
mean decrease of $1,991 per patient. Among the 58 patients who continued olanzapine therapy for
the 12 months there were significant decreases in the hospital and emergency costs but significant
increases in the medication and outpatient costs.
The results of this study indicated a significant decrease in hospital and emergency costs
even though it failed to achieve significance in total RU. Olanzapine users incurred increased
medication and outpatient costs but this was offset by the decrease in hospital and emergency
visits. The study results indicated that olanzapine users were able to achieve positive clinical
outcomes through decreased Positive and Negative Syndrome Scale (PANSS) and the declining
RU suggesting that off-label treatment of mental health conditions with olanzapine could be costeffective.
Several limitations existed with this study. First, the authors note that there could have been
undetected or unaccounted changes in the health care policy that they were unaware of which could
have resulted in decreased RU. Second, the population included in the study was eligible to receive
treatment through the BHCS because of the severity of illness, therefore it may be relatively easier
to show clinical improvement and decreased RU. Another limitation stated by the authors is the
lack of control group due to which one cannot establish causality between olanzapine use and the
decreased RU.
Apart from the limitations stated by the authors, the study also lacks generalizable results
since the study consists of severely ill patients who are eligible to receive state provided financial
coverage in one small health system in California. These patients are a small subset of the
population and therefore the results cannot be extrapolated to a larger population. As with the
previous studies, the sample also consisted primarily of a young group of patients. Despite the
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limitations, the study does provide evidence that olanzapine use shifts costs away from
hospitalization and emergency costs towards medication and outpatient costs.
The three studies that have evaluated RU among off-label AAPs users have found mixed
results. One study showed that RU varied by the specific AAPs used with quetiapine being the
preferred drug of choice to decrease hospitalizations and emergency department visits (Lage et al.,
2006). The other two studies concluded that AAPs use does decrease inpatient and emergency
visits but reached different conclusions regarding outpatient visits. Al-Zakwani et al. reported
lower outpatient visits while Del Paggio et al. reported an increase in the number of outpatient
services and costs.
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2.2 Gaps in Literature

To the best of our knowledge, there are only three studies that have assessed RU among those
who are using AAPs for off-label treatment of mental health conditions. All used data from private
claims data or from a specific county operated mental health care system. By using data from
private sources, the results are only applicable to a similar segment of the population. None of the
studies evaluated RU from a public payer perspective.
Another gap in the literature is that all the studies either exclusively included patients less than
65 years of age or had minimal patients over 65 years of age since the source of data was private
payers and not Medicare. As discussed in the earlier section, elderly patients over 65 years are
most vulnerable among adults to the adverse effects of AAPs and this cohort of patients are usually
excluded from studies. There is a need to conduct studies that focus on elderly AAPs users and
assess RU pattern and risks in this cohort.
Another feature common to all three studies is that none of them evaluated RU solely among
off-label AAPs users. The studies included patients with a myriad of mental health conditions
including schizophrenia and bipolar disorder for which treatment with AAPs is FDA approved.
No study has assessed RU among patients who are solely using the AAPs for off-label treatment.
Finally, as mentioned earlier, all three studies used data from private sources and therefore the
results are not generalizable to a large population.
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Chapter 3: Resource Utilization Patterns and Costs Associated with Off-label
Use of AAPs in a Community-Dwelling Adult Population

Specific Aim I: Examine RU patterns and estimate costs among off-label AAPs users
and non-users in a nationally representative sample

3.1 Methods
Study Design: A retrospective cross-sectional study was conducted using a publicly
available national database to compare RU and costs among respondents using AAPs off-label to
treat mental health conditions to those not using AAPs.
Data Source: This retrospective study was done using Medical Expenditure Panel Survey
(MEPS) data that is sponsored by the Agency for Healthcare Research and Quality (AHRQ).
MEPS is a nationally representative survey of civilian non-institutionalized US individuals and
households, that collects information on patient demographics, employment, income, access to
health care, health care use, medical expenditures, insurance coverage and sources of payment.
MEPS can be used to produce national estimates of health care RU and expenditures. Household
survey data are collected by computer-assisted personal interviews. Each year MEPS enrolls a new
sample of households which is followed for 2.5 years over five interviews. This study utilized the
household component of the MEPS data from 2009-2013. Five years of data were pooled to
increase the sample size and reduce the standard error of the estimates. Since each year represents
a nationally representative sample for that given year, respondents were included twice if they
completed all five panel interviews during the span of two consecutive years. Even though this led
to correlation in the data from year to year, specifying the stratum and the primary sampling unit
(PSU) in the variance estimation accounted for any correlation. All information on patient
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characteristics, RU and costs were obtained from the Full-Year Consolidated files, information on
chronic conditions was obtained from the Medical Conditions files and information on medication
use was obtained from the Prescribed Medicines event files.
Study sample: The study included all MEPS respondents 18 years and older who reported
a diagnosis for a mental health condition for which treatment with AAPs would be off-label. That
is, all patients with schizophrenia or bipolar disorder were excluded. In this study, mental health
conditions were identified using the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM). Since only schizophrenia (ICD-9-CM: 295) and bipolar
disorder (ICD-9-CM: 296) have received approval to be treated with AAPs, all other mental health
conditions (ICD-9-CM: 290-319) were defined as conditions for which treatment with AAPs
would be off-label and were included in the study sample.
Exposure: The study sample was categorized into users and non-users based on their AAPs
use. Respondents were categorized as users if they had at least two claims for an AAP within the
same year. AAPs medications were identified using the therapeutic sub-classification variable
(TC1S1_1) in the Prescribed Medicines file.
Independent variables: The primary independent variable was AAPs use. Covariates
included age, gender, race, education, marital status, insurance, income level and the Charlson
Comorbidity Index (CCI) score. The demographic variables were categorized as following: age in
two categories of 18-64, 65 and older; race in three categories of White, Black and other; education
in three categories of high school or less, some college or more and never went to school; marital
status in four categories of married, widowed, divorced/separated, and never married; insurance in
three categories of private, public and uninsured; and income level in four categories of poor, low,
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medium and high. Comorbidities were measured using the CCI, a continuous variable, which was
calculated using ICD-9-CM codes.
Outcomes: The primary outcome of interest in the study was select RU (office-based
medical provider visits, outpatient visits, inpatient visits and emergency room visits) for the given
year. The secondary outcome of interest was the person-level mean health care expenditure per
year. Drug expenditures were included in the expenditure variable. In MEPS, expenses are defined
as payments for care from all sources. These include patient out-of-pocket and all third party payers
(e.g., Medicare, Medicaid, private insurance, others).
Statistical analyses: Demographic characteristics of AAPs users and non-users were
compared using chi-square tests. The unadjusted mean RU and expenditures for users and nonusers were compared using t-tests. Multivariable logistic regression models were used to assess
the association between AAPs use and RU. Several regression models were developed to model
overall RU, inpatient use, office-based medical provider use, outpatient use and emergency room
use. The variables controlled for in the regression models included age, gender, race, education,
marital status, insurance, income and CCI.
Generalized linear model (GLM) was used to estimate the adjusted medical costs
associated with off-label use of AAPs. Due to the presence of excessive zero costs and highly
skewed data, traditional ordinary least square (OLS) estimates are ineffective in modeling costs
data. Even though log-transformed OLS can account for skewed data, the retransformation to the
original scale makes interpretation of the estimates difficult. Additionally, heteroscedasticity in the
data might also lead to biased estimates. Therefore a GLM model with the appropriate link function
is more appropriate to model cost data as it relaxes the assumptions of normality and
homoscedasticity. A GLM with gamma distribution and a log link was used to estimate costs.

26

Since the number of observations with zero costs was less than 6% in our study a 2-part model
was not used.
To generate national estimates, the complex sampling design of the MEPS dataset was
taken into account by using person-level weights, primary sampling unit and variance estimation
strata. All statistical analyses were conducted using SAS software version 9.4 (SAS Institute, Cary,
NC) and STATA software version 12. A p-value < 0.05 was considered statistically significant.
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3.2 Results

Of the survey respondents in 2009-2013, 18,246 (weighted N= 40,939,089) respondents
were adults 18 years and older who reported being diagnosed with an off-label mental health
condition. This sample of MEPS respondents had positive weights and was included in the final
analysis. Of these, 3.5% (weighted n=1,422,307) were AAPs users and the remaining 96.5% were
non-users (Figure 1).
Figure 1: Prevalence of AAPs use in respondents
without FDA approved indications
AAPS Nonusers, 96.50%

AAPs Users,
3.50%

Study population characteristics: Table 2 reports the demographic characteristics of
survey respondents included in the study. Statistical differences among users and non-users were
found for race, education, marital status, insurance, income level and the CCI score. AAPs users
were more likely to be black (15.80%), high school educated or less (55.64%), never married
(34.31%), with public insurance (46.41%) and poor income (37.09%) as compared to the nonusers. The CCI score was significantly higher (1.24+0.05) among users.
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Table 2: Demographic characteristics of study population
Characteristic

Age
18-64
65+
Gender
Male
Female
Race
White
Black
Other
Education
High school or less
Some college or more
Never been to school
Marital Status
Married
Widowed
Divorced/separated
Never married
Insurance
Private
Public
Uninsured
Income
Poor
Low
Medium
High
CCI (SE)

AAPs users (%)
(Unweighted N =770)
(Weighted N=1,422,307)

AAPs non-users (%)
(Unweighted N=17,476)
(Weighted N=39,516,782)

82.36
17.64

79.88
20.12

p-value

0.2904

0.1561
40.77
59.23

36.36
63.64
<0.0001

79.34
15.80
4.86

88.07
7.18
4.75
<0.0001

55.64
43.36
1.00

43.22
56.62
0.16
<0.0001

30.86
11.11
23.72
34.31

48.00
8.42
19.81
23.77
<0.0001

47.04
46.41
6.55

66.80
22.90
10.30
0.0001

37.09
16.58
22.25
24.08
1.24 (0.05)

19.55
13.63
30.18
36.64
1.05 (0.01)

0.0007

Abbreviation used: CCI, Charlson Comorbidity Index

Unadjusted RU and costs in off-label AAPs users: Respondents using AAPs had more
office-based provider visits, emergency room visits and inpatient visits, and higher mean officebased provider, inpatient, prescription and total costs compared to non-users (Table 3). Users were
estimated to have unadjusted mean total costs of $15,157 per respondent relative to non-users of

29

$7,304 (p<0.0001). Therefore, the total cost for people 18 years and older with an off-label mental
health condition using AAPs (weighted N=1,422,307), was estimated to be $21.5 billion.
Table 3: Mean utilization and expenditures among respondents by AAPs use
Utilization Measure (#)
Office based provider visits
Outpatient visits
Emergency room visits
Inpatient visits
Expenditure Measure ($)
Office based provider visits
Outpatient visits
Emergency room visits
Inpatient visits
Prescription
Total

AAPs users
Mean (SE)
15.1 (1.02)
1.20 (0.26)
0.49 (0.05)
0.37 (0.05)

AAPs non-users
Mean (SE)
9.93 (0.19)
0.84 (0.05)
0.33 (0.01)
0.17 (0.01)

AAPs users
Mean (SE)
2,474 (186)
844 (144)
437 (72)
4,887 (900)
6,516 (423)
15,157 (1226)

AAPs non-users
Mean (SE)
1,953 (47)
673 (37)
311 (11)
2,223 (98)
2,144 (5)
7,304 (151)

p-value
<0.0001
0.1875
0.0022
<0.0001
p-value
0.0063
0.2562
0.0800
0.0033
<0.0001
<0.0001

Abbreviation used: SE, standard error

Adjusted RU in off-label AAPs users: After adjusting for covariates, off-label AAPs user
was associated with greater resource utilization (Table 4). The odds of having an office based
outpatient or inpatient visit were significantly higher among respondents who used AAPs off-label
to treat their mental health conditions as compared to respondents not using AAPs. The odds of
using any health care resource among users were also twice the odds of non-users (p=0.0006).
Table 4: Adjusted regression model estimates for resource utilization by AAPs use
Resource Utilization
Office based outpatient visits
Outpatient visits
Emergency room visits

OR
2.47
1.28
1.09

Lower 95%CI
1.55
0.96
0.87

Upper 95% CI
3.92
1.71
1.38

p-value
0.0001
0.0873
0.4476

Inpatient visits
Any utilization

1.63
2.42

1.26
1.46

2.1
4.03

0.0002
0.0006

Abbreviation used: OR, odds ratio; CI, confidence interval
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Adjusted costs in off-label AAPs users: Office based visits and prescription costs were
found to be significantly higher among those using AAPs as compared to non-users (p<0.0001).
Inpatient and prescription costs were the major contributors to costs.
Table 5: Adjusted cost estimates for respondents with off-label mental health conditions
Resource Utilization
Office based outpatient
visits
Outpatient visits
Emergency room visits
Inpatient visits
Prescription

AAPs Users
Mean ($)
SE
189
1,943

AAPs non-users
Mean ($)
SE

p-value

1,436

107

<0.0001

1,632
1,722
24,543

324
280
4580

1,457
1,438
18,839

235
122
2372

0.4255
0.1935
0.0643

4,153

354

1,252

88

<0.0001

3.3 Discussion

The sample used in these analyses was MEPS respondents greater than 18 years with
mental health conditions not approved by the FDA to be treated with AAPs. Based on this study,
3.5% of the non-institutionalized US population with conditions other than schizophrenia or
bipolar disorder was AAPs users. The typical AAPs user was a 18-64 year old white female with
a high school education, never married with a very low income. Compared to those not using
AAPs, users also had higher proportion of respondents who were on public insurance and had
higher comorbidity index. These results were similar to what was reported by Domilano & Swartz
in a study which examined changes in prevalence of AAPs use from 1996/1997 to 2004/2005 in a
MEPS sample. The study reported AAPs users to be primarily 18-64 year old, white females with
low family income and public insurance (Domilano & Swartz, 2008).
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This study found that AAPs users had higher odds of having an office-based outpatient and
inpatient visit after adjusting for covariates age, gender, race, education, income, insurance,
marriage status and comorbidity index. Users also had higher odds of having any RU as compared
to non-users. Office based visit costs and prescription costs were found to be significantly higher
among AAPs users as compared to non-users (p<0.0001).
These results were not similar to what was reported in the study by Al-Zakwani et al. in a
private health plan sample comprised 6 to 65 year olds with any mental health conditions (AlZakwani et al., 2003). They reported AAPs users to have fewer office visits, hospital admissions,
and hospital-based outpatient visits compared to those using typical AAPs. These differences could
be due to the different sample (private health plan beneficiaries’ vs. survey respondents) and
different comparator groups (typical antipsychotic users vs. respondents with mental health
conditions without AAPs claims). In the study by Lage et al., the authors found that among
individuals with dementia, depression, schizophrenia and bipolar disorder, patients using
olanzapine and risperidone experienced significantly higher rates of hospitalizations and
emergency room visits from baseline to post treatment and patients using quetiapine experienced
significantly lower hospital admission rates and emergency visits from baseline to post treatment
(Lage et al., 2006). Our study reflects the pattern that was observed in the olanzapine/risperidone
cohort but no conclusions can be determined until the RU pattern by AAPs agent is determined.
Even though AAPs use has evidence for efficacy in patients with schizophrenia and bipolar
disorders (Maglione et al., 2011) and may improve quality of life due to lower risk of EPS and
related disorders, these benefits may be overshadowed by their propensity to cause metabolic risks
(Gareri et al., 2014). Therefore the use of these agents in treating conditions not FDA approved or
backed by evidence such as OCD and PTSD, may only further increase health care RU and costs.
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With increasing affordability as more of these drugs come off patent, there could be a further
increase in the rate of use of AAPs to treat off-label mental health conditions.
On the other hand, restrictive policies introduced by regulatory bodies, such as the CMS
partnerships to decrease AAPs use in elderly population, aim to decrease the use of AAPs
especially in a vulnerable population. These steps are backed by the premise that most off-label
use is not backed by clinical evidence. Even though these steps are undertaken to ensure the safety
of the patients, it raises the question of whether these policies are also restricting access to much
needed medications for certain patients.
Limitations
This study provided an initial insight into the pattern of RU and costs among off-label AAPs users
in a non-institutionalized US population. GLM was used to describe costs controlling for
differences between users and non-users. There are also some limitations in the study. First, the
cross-sectional study design does not help establish causality; it can only identify an association
between off-label AAPs use and higher RU and costs. It is therefore important to conduct a
longitudinal cohort study design to establish a causal relationship. Second, the users and non-users
were different in their baseline characteristics since this was not a randomized controlled trial. We
tried to address this limitation within the scope of the project by controlling for such variables in
the regression models even though we could not control for variables such as severity of disease.
Third, since MEPS is collected from self-reported surveys, there is the possibility of selection and
recall bias. Since mental health conditions are often associated with stigma, patients may
underreport the presence of these conditions. This could potentially underestimate the prevalence
of mental health conditions despite the presence of medication claims. On the other hand, patients
who are active participants in their health may be more likely to be a MEPS respondent leading to
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selection bias. Fourth, MEPS data only allows for identification of ICD-9 codes up to three digits;
therefore patients with bipolar disorder and depression (identified using ICD-9-CM: 296) were
grouped in one category thereby overestimating the FDA approved use. A longitudinal study using
claims data (described in the next section) was done to address some of these limitations.
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Chapter 4: Methods
This chapter describes the methods used to address specific aims II, III, IV and V. It includes
details on data source, study design, study population, variables and statistical analyses.
Data source
The data used in this project was obtained from the Centers for Medicare and Medicaid
Services (CMS). The study employed data from 2008 to 2010 Chronic Condition Data Warehouse
(CCW) Medicare files which are managed by the Research Data and Assistance Center (ResDAC).
A random sample of one million beneficiaries and their beneficiary summary, inpatient, outpatient
and prescription claims were used in the study. Beneficiary information was de-identified and a
unique patient identification number was used to link the beneficiaries across files.
This particular data source was used for this study since Medicare is a good source of
information for people over 65 years. Using Medicare data enables capturing real data on an elderly
population who are normally excluded from adult studies and adults over 18 years who are eligible
for Medicare due to their disability. Additionally, the use of a claims database removes the
potential for recall and self-reported bias that are associated with survey data.
A number of files were used to meet the study objectives. The Master Beneficiary
Summary File (MBSF) was used to identify demographic and enrollment eligibility information.
The inpatient, outpatient and prescription drug event (PDE) files were used to identify claims for
RU and to compute costs. The CCW Chronic Conditions File and Other Chronic Conditions file
were used to identify comorbidities including mental health conditions. The files and the variables
that have been used are described below.
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Table 6: Master Beneficiary Summary File (MBSF)
SAS Variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

AGE

Beneficiary’s age at the end of the year

SEX

Beneficiary’s gender

RACE

Beneficiary’s race was categorized as White, Black and Others

ESRD_IND

Indicator of End-stage Renal Disease (ESRD)

CREC

Current reason for Medicare entitlement, used to identify
beneficiaries with disabilities

A_MO_CNT

Count of months with Part A coverage, used to identify
continuous Part A enrollment

B_MO_CNT

Count of months with Part B coverage, used to identify
continuous Part B enrollment

PLNCOVMO

Count of months with Part D coverage, used to identify
continuous Part D enrollment

CNTRCT

Type of Part D contract, used to identify those with stand-alone
drug plan to serve as proxy for fee-for-service beneficiaries

HMO_MO

Number of months of HMO coverage, used to identify
beneficiaries with fee-for-service versus HMO coverage
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Table 7: Inpatient and Outpatient files
SAS Variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

CLM_ID

Unique encrypted claim identification number used to identify
duplication of claims

PMT_AMT

Amount paid by Medicare for the services covered by claim

UTIL_DAY

Number of days utilized by claims, used in calculating amount
paid by Medicare not included in the claim payment amount

PER_DIEM

Pass through amount not included in the claim payment amount

PRPAYAMT

Amount paid by primary payer if not Medicare

DED_AMT

Beneficiary deductible amount

COIN_AMT

Beneficiary coinsurance amount

BLDDEDAM

Beneficiary blood deductible liability amount

ADMTG_DGNS_CD

Admitting diagnosis ICD-9-CM code

PRNCPAL_DGNS_CD

Primary diagnosis ICD-9-CM code

ICD_DGNS_CD1-25

Claim diagnosis code
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Table 8: Part D Event (PDE) file
SAS Variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

PDE_ID

Unique encrypted prescription claim identification number used
to identify duplication of claims

SRVC_DT

Date of service of prescription claim

PTPAYAMT

Amount paid by patient for claim

CPP_AMT

Amount paid by Medicare for claim

GNN

Generic name of drugs
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Table 9: MBSF Chronic Conditions and Other Chronic Conditions files
SAS Variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

AMI

Acute myocardial infarction

ALZ

Alzheimer’s disease

CHRNKIDN

Chronic kidney disease

COPD

Chronic obstructive pulmonary disease

CHF

Congestive heart failure

DIABETES

Diabetes Mellitus

RA_OA

Rheumatoid and Osteoarthritis

CNCRBRST

Breast cancer

CNCRCLRC

Colorectal cancer

CNCRPRST

Prostate cancer

CNCRLUNG

Lung cancer

DEPRESSN

Depression

ANXI_MEDICARE

Anxiety disorders

AUTISM_MEDICARE

Autism spectrum disorders

BIPL_MEDICARE

Bipolar disorder

ACP_MEDICARE

ADHD, conduct disorders and hyperkinetic syndrome

INTDIS_MEDICARE

Intellectual disabilities and related conditions

LEADIS_MEDICARE

Learning disabilities

OTHDEL_MEDICARE

Other developmental delays

PSDS_MEDICARE

Personality disorders

PTRA_MEDICARE

Post-traumatic stress disorder

SCHI_MEDICARE

Schizophrenia

SCHIOT_MEDICARE

Schizophrenia and other psychotic disorders
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Approvals
The proposal for this project was approved by the Virginia Commonwealth University
institutional review board (IRB) under expedited review. In addition, the proposal was also
approved by ResDAC and CMS.

4.1 Specific Aim II
Specific Aim II: Evaluate the prevalence of off-label and on-label use of AAPs and describe
patient characteristics in a Medicare population.

Study design
A retrospective, cross-sectional study was employed using Medicare secondary databases
to compute the prevalence of off-label and on-label use of AAPs. AAPs users were identified and
the prevalence of off-label and on-label use in 2008, 2009 and 2010 was computed.
Population of interest
For the first Specific Aim, the population of interest was AAPs users 18 years and older
within each year. Beneficiaries were considered to be AAPs users if they had at least two claims
(>1 day and < 60 days apart) for AAPs during the year. A minimum of two claims for the same
agent was chosen to eliminate beneficiaries who had been given a one-time dose as part of their
emergent care. Only AAPs with registered National Drug Codes (NDC) numbers before January
1, 2008 were included in the study. The drugs and their FDA approved indications have been
denoted in Table 10 as obtained from the FDA website
https://www.accessdata.fda.gov/scripts/cder/drugsatfda/
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Table 10: List of atypical antipsychotics agents of interest
Drug Name

FDA approved indications before January 1, 2008

Olanzapine (Zyprexa)

-Oral: Schizophrenia, Bipolar disorder (monotherapy and
in combination with lithium or valproate)
-IM: agitation associated with schizophrenia or bipolar
mania

Quetiapine (Seroquel)

Schizophrenia, Bipolar disorder (Depression, mania,
maintenance)

Risperidone (Risperdal)

Schizophrenia, Bipolar (manic or mixed) disorder
(monotherapy and in combination with lithium or
valproate)

Aripiprazole (Abilify)

Schizophrenia, Bipolar (Manic or mixed), adjunctive
therapy to Major Depressive disorder (adjunct to AD)

Ziprasidone (Geodon)

Oral: Schizophrenia, Bipolar Mania
IM: Acute agitation in schizophrenic patients

IM: Intra-muscular AD: Anti-depressants
Off-label use: For this study, an indication-based definition of off-label use was applied
i.e., indications that were not approved by the FDA to be treated with AAPs were categorized as
off-label use. All the AAPs of interest have been approved by the FDA for the treatment of
schizophrenia and bipolar disorder. Therefore use of AAPs in absence of these two indications was
deemed off-label use. Claims for mental health conditions were identified using the International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. These
diagnosis claims were identified from the principal diagnosis, admitting diagnosis or any of the 25
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ICD-9-CM variables in the inpatient and outpatient file or from the Other Chronic Conditions file.
All AAPs users who had at least one inpatient or two outpatient claims for schizophrenia (ICD-9CM: 295.xx) and/or bipolar disorder (ICD-9-CM: 296.0, 296.1, 296.4 – 296.9) were classified as
FDA approved or on-label users. All other AAPs users were considered off-label users.

Statistical Analysis
Descriptive analysis of the study population was conducted. Continuous variables were
described using means and standard deviation and categorical variables were described using
counts and percentages. Prevalence of off-label and on-label use of AAPs for each year was
calculated as follows:

𝑂𝑓𝑓𝑙𝑎𝑏𝑒𝑙 𝑈𝑠𝑒 = 100 𝑋

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑆𝑐ℎ𝑖𝑜𝑝ℎ𝑟𝑒𝑛𝑖𝑎 𝑜𝑟 𝐵𝑖𝑝𝑜𝑙𝑎𝑟 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑢𝑠𝑖𝑛𝑔 𝐴𝐴𝑃𝑠

𝑂𝑛𝑙𝑎𝑏𝑒𝑙 𝑈𝑠𝑒 = 100 𝑋

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑤𝑖𝑡ℎ 𝑆𝑐ℎ𝑖𝑜𝑝ℎ𝑟𝑒𝑛𝑖𝑎 𝑜𝑟 𝐵𝑖𝑝𝑜𝑙𝑎𝑟 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑢𝑠𝑖𝑛𝑔 𝐴𝐴𝑃𝑠

The pattern of use of AAPs and indications for use were reported as percentages along with
the characteristics of beneficiaries using AAPs off-label and on-label. All statistical analyses were
conducted using SAS 9.4.
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4.2 Specific Aim III and IV
Specific Aim IIIA: Compare all-cause RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for off-label treatment of mental health conditions.

Specific Aim IIIB: Compare mental health RU and costs between Medicare beneficiaries
using AAPs and those not using AAPs for off-label treatment of mental health conditions.

Specific Aim IVA: Compare all-cause RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for on-label treatment of mental health conditions.

Specific Aim IVB: Compare mental health RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for on-label treatment of mental health conditions.

Study design and index period
For Specific Aims III and IV a retrospective cohort study design was employed using
Medicare 2008-2010 data. For this section of the study January 1, 2009 – December 31, 2009 was
defined as the index period enabling the use of 12 months of baseline and 12 months of follow up
period.
Eligibility criteria
From the random sample of one million beneficiaries only those with fee-for-service
benefit and continuous Medicare enrollment from 2008-2010 across Part A, Part B and Part D
were included. Fee-for-service beneficiaries were identified using the CNTRCT and HMO_IND
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variables from the MBSF files. Beneficiaries with a “Stand Alone Prescription Drug Plan” with
zero months of HMO coverage were considered to be fee-for-service beneficiaries. To have
continuous enrollment beneficiaries had to have 12 months of Part A, B and D access as denoted
in the A_MO_CNT, B_MO_CNT and PLNCOVMO variables for each year from January 1, 2008
to December 31, 2010.
Population of interest
The population of interest was Medicare beneficiaries 18 years and older with a mental
health condition. Even though Medicare is primarily for patients over 65 years of age, beneficiaries
who are 18 to 64 years of age were also included since severe mental illness is prevalent among
Medicare beneficiaries under 65 years who are entitled to Medicare due to a disability. According
to the Social Security Administration around 37% of all the Medicare disabled beneficiaries have
severe mental disorders (SSA, 2011). The presence of mental health conditions was identified
using one of two methods:
(3) Beneficiaries had to have at least one inpatient or two outpatient mental health claims
between January 1, 2008 and December 31, 2010. Mental health claims were identified
using ICD-9-CM codes. These claims were identified from the principal diagnosis,
admitting diagnosis or any one of the 25 ICD-9-CM variables in the inpatient and
outpatient files. Mental health claims were identified using ICD-9-CM codes 290.xx –
319.xx as presented in Table 11.
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Table 11: List of ICD-9-CM codes for mental health conditions from inpatient/outpatient files
ICD-9-CM

Condition

ICD-9-CM

Condition

290.xx

Dementia

298.xx

Non-organic psychoses

291.xx

Alcoholic psychoses

299.xx

Psychoses with childhood
origin

292.xx

Drug psychoses

300.xx

Anxiety and neurotic
disorders

293.xx

Transient organic psychoses

301.xx

Personality disorders

294.xx

Other organic psychoses

302.xx

Psychosexual disorders

295.xx

Schizophrenia

303.xx –

Psychoactive substance abuse

305.xx

disorders

306.xx –

Other mental disorders

296.0,

Bipolar disorder

296.1,

310.xx

296.4-296.9
296.2,

Depression

296.3, 311.xx
297.xx

Paranoid states

312.xx –

Other child and adolescent

316.xx

origin mental disorders

317.xx –

Mental Retardation

319.xx

(ii) Beneficiaries who were flagged as having specific mental health conditions in the
MBSF Other Chronic Conditions file were also included in the study sample. Medicare uses this
file to flag beneficiaries who have had at least one inpatient or two outpatient claims for a particular
condition since the beneficiary enrolled in Medicare. The conditions identified from this file are
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presented in Table 12. The variables in the Other Chronic Conditions file were reassigned to
different categories of mental health conditions to match the categories described in Table 11.
Table 12: List of mental health conditions identified from Other Chronic Conditions File
Variable (As denoted in Medicare)

Condition (Reassigned variable names)

Depression; Depressive disorders

Depression

Alzheimer’s disease

Dementia

Anxiety disorders

Neurotic disorders

Autism spectrum disorders

Psychoses with childhood origin

Bipolar disorder

Bipolar disorder

ADHD,

conduct

disorders;

Learning Other child and adolescent origin mental

disabilities; Other developmental delays

disorders

Intellectual disabilities

Mental retardation

Personality disorders

Personality disorders

Post-traumatic stress disorder

Other mental disorders

Schizophrenia;

Schizophrenia

and

other Schizophrenia

psychotic disorders

Study groups
The population of interest was then divided into two groups for each Specific Aim.
Beneficiaries who had a diagnosis of schizophrenia and/or bipolar disorder were categorized as
the on-label cohort. Beneficiaries who did not have claims for schizophrenia and/or bipolar
disorder were categorized as the off-label cohort. The off-label cohort was used in the analysis of
Specific Aim II and the on-label cohort for Specific Aim III.
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Exposure variable
The exposure of interest for Specific Aims III and IV was AAPs use during the index
period. Beneficiaries were considered to be AAPs users if they had at least two claims (>1 day and
< 60 days apart) for the same antipsychotic agent between January 1, 2009 and December 31,
2009. The AAPs of interest were aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine
(Seroquel), risperidone (Risperdal) and ziprasidone (Geodon) and were identified using their
generic names. The off-label cohort and the on-label cohort were further divided based on their
AAPs use. The groups identified were:
Specific Aim 2: Off-label AAPs user and Off-label AAPs non-user
Specific Aim 3: On-label AAPs user and On-label AAPs non-user
Exclusion criteria
Beneficiaries who met the following criteria were excluded from the study.
1) Beneficiaries who had claims for both an off-label and on-label mental health condition
were excluded from the study analysis in order to create two mutually exclusive groups. These
beneficiaries were excluded since there was no conclusive evidence to identify whether or not the
AAPs were being used to treat on-label conditions.
2) Beneficiaries with prescription claims for asenapine (Saphris), lurasidone (Latuda) and
iloperidone (Fanapt) were excluded from the study since these agents received FDA approval
during and not at the beginning of the index period. Similarly beneficiaries with claims for
olanzapine/fluoxetine (Symbyax) and 47aliperidone (Invega) were excluded from the study since
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these agents received approvals for only one of the two FDA approved conditions (schizophrenia
or bipolar disorder).
3) Among beneficiaries identified as AAPs non-users, those with prescription claims for
AAPs of interest in 2008 were excluded to ensure that the non-users were truly not using AAPs
during the study period.
After the exclusions were applied to the patient population, the final groups were identified for
propensity score matching (Figure 2).
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Fee-for-service beneficiaries (≥18 years) with continuous enrollment in Part A, B, and D with
mental health conditions

Exclude beneficiaries with both on-label and off-label mental health conditions

Off-label cohort

Off-label AAPs Users

On-label cohort

Off-label AAPs

On-label AAPs Users

Non-Users

On-label AAPs
Non-Users

Exclude beneficiaries with claims for newer AAPs

Exclude beneficiaries with claims for AAPs in 2008 among Non-Users

Specific Aim 2:

Specific Aim 2:

Specific Aim 3:

Specific Aim 3:

Off-label Users

Off-label Non-Users

On-label Users

On-label Non-Users

Figure 2: Flowchart of inclusions and exclusions from original sample
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4.3 Specific Aim V
Specific Aim V: Evaluate differences in RU and associated costs in Medicare
beneficiaries using AAPs and those not using AAPs to treat specific mental health
conditions.

After the eligible population of interest was identified as described for Specific Aims 3 and 4 the
study groups for Specific Aim 5 were identified.
Study groups:
The population of interest that met the eligibility criteria was further divided into mutually
exclusive groups based on the presence of certain mental health diagnoses. These disease states
were identified using ICD-9-CM codes: schizophrenia (ICD-9-CM: 295.xx), bipolar disorder
(ICD-9-CM: 296.0, 296.1, 296.4 - 296.9), depression (ICD-9-CM: 296.2, 296.3, 311.xx), dementia
(ICD-9-CM: 290.xx, 294.00, 294.10, 294.11, 294.20, 294.21, 294.8), post-traumatic stress
disorder (ICD-9-CM: 309.81) and obsessive compulsive disorder (ICD-9-CM: 300.3). The
exposure of interest was AAPs use as described earlier and the groups were categorized into AAPs
users and non-users.
Matching: To control for observable differences, the groups were matched using
propensity score matching. For Specific Aim III, the off-label users and non-users were matched,
for Specific Aim IV the on-label users and non-users were matched, and for Specific Aim V, the
AAPs users and non-users within each study group were matched. Matching was used to address
potential selection bias and confounding between the study groups. The propensity score or the
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probability of having prescription claims for AAPs of interest was estimated using logistic
regression wherein AAPs use was coded as a dummy outcome variable.
Covariates: The covariates in the logistic regression model included age, gender, race, endstage-renal-disease indicator, disability indicator, number of unique medications, CharlsonComorbidity Index (CCI), mental health conditions, and non-mental health inpatient and outpatient
visits during the pre-index period.
Age:
This variable was identified from the MBSF file and was coded as a continuous variable
based on the age of the beneficiary at the end of 2008. Age, found to affect RU in patients with
mental health disorders (Ginsberg et al., 1997, Twomey et al., 2015), was also coded as categories
“65 years and under” and “Greater than 65 years” for descriptive purposes.
Gender:
This variable was identified from the MBSF file and was coded as a dummy variable. Men
and women had different comorbid mental health condition profiles (Sajatovis et al., 1997, Dagher
et al., 2015, Twomey et al., 2015) therefore the variable was retained in the model. For example,
the study by Twomey et al. reported that adult female patients with mental disorders were
associated with increased health service utilization.
Race:
This variable was identified from the MBSF file and was collapsed to variables “White”,
“African American” and “Others”. Disparities in mental health care utilization among the different
races, especially among non-white ethnicities, were reported in previous studies (Wu et al., 2012,
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Twomey et al., 2015). In order to control for any disparities, this variable was introduced in the
propensity model.
End-Stage-Renal-Disease (ESRD):
This variable identified from MBSF was coded as a dummy variable. This variable denotes
if the beneficiary has been diagnosed with ESRD, which could also be the reason they are eligible
for Medicare even if they are younger than 65 years. ESRD is associated with increased health
care costs and RU (Khan et al., 2002; Blanchette et al., 2015) and accounted for 7.1% of overall
Medicare paid claims (USRDS, 2014).
Disability:
This variable was identified from the MBSF file and was coded as a dummy variable to
indicate presence or absence of disability. This was an important variable to include since
beneficiaries who are eligible for Medicare due to their disability versus their age might have
different RU compared to Medicare beneficiaries over 65 years of age (Ettner, 1998).
Unique number of medications:
This quantitative variable was calculated from the PDE file using prescription claims data.
Unique medications were identified using the GNN variable which lists the drug in its generic
name. This is an important variable to control for since increased medication use such as
antidepressant and typical antipsychotic use has led to increased RU (Sheehan et al., 2012).
Charlson Comorbidity Index:
Comorbidity was found to be significantly associated with RU among patients with mental
disorders (Twomey et al., 2015) and therefore was added to the propensity model. The CCI
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variable was a continuous variable that assigned scores to each beneficiary based on the presence
of 17 comorbid conditions. The conditions were identified using inpatient claims, outpatient
claims, the Chronic Conditions file, and the Other Chronic Conditions CCW files using ICD-9CM codes (Table 13). This variable was used in retrospective claims database studies to account
for beneficiary comorbid condition, disease severity and mortality risk (Charlson et al., 1987).
Even though several adaptions of this variable had been made, Deyo et al. adapted one based on
ICD-9-CM codes for administrative data (Deyo et al., 1992) and was used in this study. For each
beneficiary, corresponding scores were identified for each comorbid condition and the sum of the
scores was the assigned CCI score. For example, a diabetic (CCI score of 1) patient with AIDS
(CCI score of 6) would have a total CCI score of seven.
Mental health conditions:
The different mental health conditions were included as dummy variables in the regression
model. The conditions were identified from the inpatient and outpatient claims (Table 11) and
from the CCW files (Table 12). Mental health comorbidities were reported to be important
predictors of RU (Twomey et al., 2015; Wu et al., 2012; Kawatkar et al., 2014) and were included
as dummy variables in the matching regression model.
Baseline RU:
The number of outpatient visits and inpatient visits were included as two separate
quantitative variables based on claims data from 2008. Baseline RU was used as a proxy variable
for severity of illness (Crivera et al., 2011; He at al., 2015).
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Table 13: Conditions included in Charlson Comorbidity Index (CCI)
Medical Condition

ICD-9-CM codes

Score

Myocardial infarction

410,412

1

Congestive heart failure

428

1

Peripheral vascular disease

441, 443.9, 785.4

1

Cerebrovascular disease

430-438

1

Chronic obstructive pulmonary disorder

490-496, 500-505, 506.4

1

Dementia

290

1

Paralysis

342, 344.1

1

Diabetes

250.0-250.3, 250.7

1

Chronic liver disease and cirrhosis

571.2, 571.4-571.6

1

Ulcers

531.0-531.7, 532.0-532.7, 533.0-533.7,
534.0-534.7

1

Rheumatoid arthritis

714.81, 725, 710, 710.1, 710.4, 714.0714.2

1

Diabetes with sequelae

250.4-250.6

2

Chronic renal failure

582,585, 586, 588, 583.0-583.7

2

Any malignancy

140-172.9, 174-195.8, 200-208.9

2

Moderate-severe liver disease

572.2-572.8, 456.0-456.1, 456.20,
456.21

3

AIDS

042-044

6

Metastatic solid tumor

196-199.1

6
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After computing propensity scores, users (cases) and non-users (controls) were matched
using the Greedy 5→1 technique (Parsons, Retrieved June 2016). In this method, cases and
controls were initially matched based on five digits of the propensity score, then matched on four
digits if appropriate matches were not found. This continued until one digit matching. This
technique was chosen since it maximizes the number of matched pairs.
Propensity score matching is framed on two theoretical assumptions; the conditional
independence assumption (CIA) and the common support condition (CSC) (Rosenbaum & Rubin,
1983). The CIA assumes that after the groups are matched and covariates are controlled, the groups
have similar probability of receiving AAPs treatment. This assumption heavily relies on the
researcher’s ability to include all variables that are relevant to the decision of receiving treatment.
This assumption cannot be directly tested and hence it is assumed that all relevant variables are
included in the model. The CSC assumes that there is sufficient overlap among the characteristics
of the cases and controls to ensure adequate matching. This assumption was tested in two ways:
1) Using a visual overlap plot of the propensity scores of the cases and controls. The scores
were plotted as box-plot and histogram plots and were visually compared to determine if
appropriate overlap existed.
2) By comparing the means of the propensity scores between cases and controls using the
Kolmogorov-Smirnov non-parametric test to statistically determine if overlap existed.
Absolute standardized difference was used to assess balance among the covariates between
cases and controls before and after matching since p-values depend on the type of statistical test
used and sample size (Sullivan & Feinn, 2012). The categorical variable Race was represented
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using binary indicator variables. Absolute standardized differences less than 10% indicated
negligible differences between the groups.
For continuous variables the absolute standardized difference is

For categorical variables,

where

and

are the means of the variables in the exposed and unexposed cohorts,

denote the variances of the variables and

and

and

denote the proportion in the groups.

Index dates: For the AAPs users the date of the first AAPs prescription claim received
during the index period (January 1, 2009 and December 31, 2009) was assigned as the index date.
AAPs non-users, since they do not have a claim for AAPs during the index period, were assigned
the corresponding date as their matched case.
Outcome measure
The primary outcome of interest was all-cause RU and associated costs during the 12
month follow up period after the index date. RU included inpatient visits, hospital outpatient visits
and prescription claims. The costs associated with these resources and total costs were also
assessed and reported. The amounts paid by Medicare and other third party payers were obtained
from the base inpatient and outpatient claims files but the beneficiary share was obtained from the
Revenue Center files which were cross-linked using unique Claim IDs. A third party payer was
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any entity, such as private health plans that paid for a share of the costs along with Medicare and
the beneficiary. The individual cost components were computed as follows:
𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 𝑠ℎ𝑎𝑟𝑒 = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑝𝑎𝑖𝑑 𝑏𝑦 𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 + (𝐷𝑖𝑒𝑚 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑎𝑖𝑑 ∗ 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑐𝑙𝑎𝑖𝑚)
𝐵𝑒𝑛𝑓𝑖𝑐𝑖𝑎𝑟𝑦 𝑠ℎ𝑎𝑟𝑒 = 𝐷𝑒𝑑𝑢𝑐𝑡𝑖𝑏𝑙𝑒 + 𝐶𝑜𝑖𝑛𝑠𝑢𝑟𝑎𝑛𝑐𝑒 + 𝐵𝑙𝑜𝑜𝑑 𝑑𝑒𝑑𝑢𝑐𝑡𝑖𝑏𝑙𝑒
𝑇𝑜𝑡𝑎𝑙 = 𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 𝑠ℎ𝑎𝑟𝑒 + 𝑇ℎ𝑖𝑟𝑑 𝑝𝑎𝑟𝑡𝑦 𝑝𝑎𝑦𝑚𝑒𝑛𝑡 + 𝐵𝑒𝑛𝑓𝑖𝑐𝑖𝑎𝑟𝑦 𝑠ℎ𝑎𝑟𝑒

All costs associated with emergency department visits were captured in either the inpatient or
outpatient billing depending on whether the patient was admitted (inpatient) or discharged
(outpatient) after their emergency visit. All positive costs were inflated to 2015 U.S. dollars using
the Medical component of Consumer Price Index (CPI) obtained from the Bureau of Labor
Statistics (BLS, Retrieved August 2016) (Table 14).
Table 14: Consumer Price Index (CPI) 2009-2015
2009

2010

2015

Prescription

391

407.8

483

Medical Care Services

397

411

483.6

The secondary outcome was mental health RU and costs. Mental health inpatient and
outpatient visits were identified using ICD-9-CM codes 290.xx – 319.xx in the principal diagnosis,
admitting diagnosis or the first three diagnosis variables in the inpatient and outpatient files.
Mental health medication costs included prescriptions for antipsychotics, antidepressants,
anxiolytics, and mood stabilizers.
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Statistical analyses
Descriptive analysis of the study population was done before matching. Continuous
variables were described using means and standard deviations and categorical variables were
described using counts and percentages. The sample after matching was described similarly and
balance between covariates was assessed using absolute standardized differences.
RU and costs were assessed for 12 months after the index date and compared between users
and non-users. RU was estimated as mean number of visits and compared using the paired t-test.
Whenever the normality assumption was violated the Wilcoxon sign-rank test was used. Normality
was assessed using Q-Q plots and Kolmogorov-Smirnov test. RU was also reported as the
percentage of beneficiaries who utilized the services. Conditional logistic regression analysis was
used to assess the risk of utilizing inpatient or outpatient services among users and non-users. For
this analyses, separate regression models were created for inpatient and outpatient visits and the
visit was dichotomized as a dummy variable.
Costs were estimated as mean inpatient, outpatient, prescription, and total costs. The
breakdown of these costs based on payers was also reported to include Medicare, beneficiary and
other primary payers. The difference in the paired costs was assessed using both the mean (paired
t-test) and the median (Wilcoxon sign-rank test and Sign test) since cost data is not normally
distributed but is typically right skewed with a long tail. The results of all 3 tests were reported as
paired t-tests are sensitive to outliers unlike the other two tests but the Wilcoxon does take into
account the extreme observations unlike the Sign test. SAS v 9.4 (SAS Institute, Cary, NC) was
used for all analyses and a significance level of α = 0.05 was set a-priori.
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4.4 Sensitivity Analyses
A sensitivity analyses is recommended anytime there is uncertainty within the data (Briggs,
1999). It is therefore good practice to examine the changes in the RU and costs patterns when some
of the assumptions in the study are varied.
1) AAPs users were defined as those beneficiaries who had claims for AAPs in 2009 which
included both existing and new users. In the sensitivity analyses all beneficiaries who had AAPs
claims in 2008 were excluded to estimate the differences in follow up RU and costs for new AAPs
users and those not using AAPs.
2) Another assumption in the study was to only include schizophrenia and bipolar disorder
as FDA approved conditions for aripiprazole even though it has been approved for adjunctive
treatment of depression. Therefore, there may be aripiprazole users with depression in the off-label
cohort, thus overestimating costs in that group. The results were tested after excluding aripiprazole
from the AAPs of interest.
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Chapter 5: Results
5.1 Specific Aim II

Specific Aim II: Evaluate the prevalence of off-label and on-label use of AAPs and
describe patient characteristics in a Medicare population.
Population of interest: In the random sample obtained from CMS for 2008 (N=891,082), 2009
(N=905,814) and 2010 (N=922,202), a cohort of 813,656 beneficiaries was followed across all
three years. Within each year the population of interest i.e. AAPs users was identified. The
beneficiaries using AAPs are described in Table 15 and the distribution of use among the AAPs is
shown in Figure 3. The prevalence of AAPs use has remained constant across the years with
majority of beneficiaries using quetiapine and risperidone.
Table 15: Overall annual trend of atypical antipsychotic users from 2008-2010

Total Beneficiaries
AAPs Users

2008

2009

2010

891,082
28,537 (3.20%)

905,814
29,280 (3.23%)

922,202
29,831 (3.23%)

Age
64.04+19.40 (18-106) 63.50+19.17 (20-106) 63.24+19.04 (20-107)
-Mean (years)
-Less than 65 years
14,065 (49.29%)
14,913 (50.93%)
15,442 (51.76%)
14,472 (50.71%)
14,367 (49.07%)
14,389 (48.24%)
-65 years and older
Sex
-Male
10,858 (38.05%)
11,296 (38.58%)
11,646 (39.04%)
Race
-White
22,560 (79.06%)
23,122 (78.97%)
23,458 (78.64%)
4,001 (14.02%)
4,068 (13.89%)
4,158 (13.94%)
-African American
1,976 (6.92%)
2,090 (7.14%)
2,215 (7.43%)
-Others
ESRD
199 (0.70%)
222 (0.76%)
204 (0.68%)
Disability
14,255 (49.95%)
15,155 (51.76%)
15,756 (52.82%)
Abbreviation used: ESRD, End-Stage Renal Disease
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PAT T E R N O F A A P S U S E F R O M
2008-2010 (%)
Aripirazole

Olanzapine

Quetiapine

Risperidone

Ziprasidone

7.63

7.48

7.40

34.60

33.01

33.53

43.13

43.75

43.95

21.47

19.76

18.59

15.31

17.40

17.33

2008

2009

2010

Figure 3: Pattern of atypical antipsychotic use from 2008-2010
Off-label use: The prevalence of off-label and on-label use of AAPs and the characteristics
of the beneficiaries are described in Table 16. Approximately 37% of total AAPs use was in the
absence of an FDA approved indication and this was consistent across the three years. More than
60% of the beneficiaries receiving AAPs for off-label treatment of mental health conditions were
older than 65 years and majority were white females without ESRD or a disability. . Among AAPs
users older than 65 years, 49% were off-label users. Majority of these beneficiaries had indications
for depression, neurotic disorders or other organic psychoses (Figure 4). In 2008, 53.8% of the offlabel AAPs users had depression and approximately 31% had dementia and other related organic
psychosis. By 2010, these numbers had decreased to 48.6% depression and 24.8% dementia and
related psychosis.
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On-label use: The prevalence of beneficiaries using AAPs in the presence of an FDA
approved indications remained 63% across the three years (Table 16). Of these on-label AAPs
users; 82.46%, 80.47% and 78.33% had diagnosis for schizophrenia and 55.47%, 56.48% and
56.91% had diagnosis for bipolar disorder in 2008, 2009 and 2010 respectively
Table 16: Patterns of off-label and on-label use of AAPs from 2008-2010

Off-label Users

2008
(N=28,537)
10,476 (36.71%)

2009
(N=29,280)
10,679 (36.47%)

2010
(N=29,831)
10,876 (36.46%)

Age
70.69+18.71 (18-104) 69.90+18.66 (20-106) 69.54+18.58 (20-107)
-Mean (years)
-Less than 65 years
3,409 (32.54%)
3,684 (34.50%)
3,867 (35.56%)
7,067 (67.46%)
6,995 (65.50%)
7,009 (64.44%)
-65 years and older
Sex
-Male
3,397 (32.43%)
3,546 (33.21%)
3,678 (33.82%)
Race
-White
8,575 (81.85%)
8,714 (81.60%)
8.846 (81.34%)
1,131 (10.80%)
1,125 (10.53%)
1,116 (10.26%)
-African American
770
(7.35%)
840
(7.87%)
914 (8.40%)
-Others
ESRD
79 (0.75%)
90 (0.84%)
73 (0.67%)
Disability
3,448 (32.91%)
3,735 (34.98%)
3,954 (36.36%)
On-label Users

18,061 (63.29%)

18,601 (63.53%)

18,955 (63.54%)

Age
60.18+18.74 (20-106) 59.83+18.48 (20-105) 59.63+18.34 (20-106)
-Mean (years)
-Less than 65 years
10,656 (59.00%)
11,229 (60.37%)
11,575 (61.07%)
7,405 (41.00%)
7,372 (39.63%)
7,380 (38.93%)
-65 years and older
Sex
-Male
7,461 (41.31%)
7,750 (41.66%)
7,968 (42.04%)
Race
-White
13,985 (77.43%)
14,408 (77.46%)
14,612 (77.09%)
2,870 (15.89%)
2,943 (15.82%)
3,042 (16.05%)
-African American
1,206 (6.68%)
1,250 (6.72%)
1,301 (6.86%)
-Others
ESRD
120 (0.66%)
132 (0.71%)
131 (0.69%)
Disability
10,807 (59.84%)
11,420 (61.39%)
11,802 (62.26%)
Abbreviation used: ESRD, End-Stage Renal Disease

62

Distribution of mental health conditions among off-label users
(%)
2010

5.88

2009

6.61

2008

7.25

18.97

22.21

23.78

48.58

32.79

52.6

7.1 5.14 7.25

35.79

53.81

7.56 5.32 7.77

35.92

7.18 5.58 8.36

Dementia

Other Organic Psychoses

Depression

Neurotic disorders

Pyschoactive substance Use

Other mental health disorders

Mental retardation
*Percent’s do not add to 100 since some patients had more than one condition

Figure 4: Distribution of mental health conditions among off-label AAPs users

In the following section the population of interest and study groups identified for Specific Aims
III, IV and V are described. This is followed by the description of the outcomes for the individual
aims.

Population of interest: From the random sample of one million beneficiaries, 238,127
beneficiaries met the eligibility criteria i.e., fee-for-service beneficiaries with three years of
continuous enrollment in Medicare Part A, B and D. Of the beneficiaries who met the eligibility
criteria N=108,937 were identified to be the population of interest (Figure 5). These beneficiaries
were greater than 18 years and had a diagnosis for a mental health condition as identified from the
inpatient, outpatient and other chronic conditions files. The population of interest was divided into
two mutually exclusive groups; the off-label cohort (N=78,708) comprised beneficiaries with any
mental health conditions except bipolar disorder or schizophrenia and on-label cohort (N=3,846)
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comprised beneficiaries with only schizophrenia and/or bipolar disorder. A subset of 26,383
beneficiaries was excluded since they had a diagnosis for both an off-label and on-label condition.
AAPs users: The off-label and on-label cohort were categorized into AAPs users and nonusers based on AAPs claims. The Part D claims file was used to identify 16,056 AAPs users with
a mental health condition in 2009. Quetiapine was the most frequently dispensed AAPs while
ziprasidone was the least frequent (Figure 6). Of these beneficiaries, 21.6% were using AAPs in
the absence of a FDA approved indication (Figure 7). The off-label and on-label cohorts were
further categorized based on their AAPs use. In the off-label cohort there were 3,468 (4.41%)
beneficiaries who were AAPs users and 1,242 (32.29%) beneficiaries were AAPs users in the onlabel cohort (Figure 5). After beneficiaries who had prescription claims for newer AAPs (N=107)
and who had prescription claims for AAPs the previous year (N=772) were excluded, the final
study groups for each Specific Aim were shown in Figure 5.
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Fee-for-service beneficiaries (≥18 years) with continuous enrollment in Part A, B, and D with
mental health conditions (N=108,937)

Exclude beneficiaries with both on-label and off-label mental health conditions (N=26,383)

Off-label cohort (N=78,708)

On-label cohort (N=3,846)

Off-label AAPs Users

Off-label AAPs

On-label AAPs Users

On-label AAPs

(N=3,468)

Non-Users (N=75,240)

(N=1,242)

Non-Users (N=2,604)

Exclude beneficiaries with claims for newer AAPs (N=107)

Exclude beneficiaries with claims for AAPs in 2008 among Non-Users (N=772)

Specific Aim 2:

Specific Aim 2:

Specific Aim 3:

Specific Aim 3:

Off-label Users
(N=3,457)

Off-label Non-Users
(N=74,557)

On-label Users
(N=1,219)

On-label Non-Users
(N=2,442)

Figure 5: Flow of beneficiaries to identify study groups for Specific Aims III and IV
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Ziprasidone

7.68

Risperidone

31.88

Quetiapine

39.67

Olanzapine

20.25

Aripirazole

17.68

Figure 6: Pattern of AAPs use among mental health beneficiaries in 2009 (%)

N=16,056
On-label Users,
78.40%

Off-label Users,
21.60%

Figure 7: Prevalence of off-label AAPs use among AAPs users in 2009
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5.2 Specific Aim III
Specific Aim IIIA: Compare all-cause RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for off-label treatment of mental health conditions.

Pre-match study groups: For this aim, the study groups identified were the off-label AAPs
user cohort (N=3,457) and the off-label AAPs non-user cohort (N=74,557) before propensity score
matching. Absolute standardized differences were computed to check for differences between the
groups (Table 17). The groups differed in their mean age, number of medications used in the
previous year, frequency of beneficiaries with disability, and prevalence of certain mental health
conditions such as depression and psychoactive substance use. Users were slightly younger than
non-users; majority of the users were less than 65 years whereas majority of the non-users were
65 to 84 years. The AAPs users took more medications compared to non-users but did not differ
from non-users in their inpatient and outpatient utilization rates.
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Table 17: Baseline characteristics of off-label cohort pre-matching
Variable
Demographic
Age (years)
<65
65-84
>=85
Male
Race
White
Black
Others
Disease Burden
CCI
No. of medications
ESRD
Disability
Mental Health Disorders
Depression
Anxiety and Neurotic d/o
Psychoactive Substance Use
Mental Retardation
Other Organic Psychoses
Other Mental Disorders
Personality
Dementia
Child and Adolescent d/o
Child Organic Psychoses
Transient Organic Psychoses
Psychosexual d/o
Drug Psychoses
Alcoholic Psychoses
Non-Organic Psychoses
Paranoiab
Resource Utilization
Inpatient
Outpatient

AAPs User
(N=3,457)

AAPs Non-User
(N=74,557)

p-valuea

Standardized
Difference (%)

66.19 + 18.44
1494 (43.22%)
1306 (37.78%)
657 (19.00%)
1138 (32.92%)

69.65 + 14.89
20423 (27.39%)
43881 (58.86%)
10253 (13.75%)
21740 (29.16%)

<0.0001

20.63

<0.0001

8.13

2874 (83.14%)
352 (10.18%)
231 (6.68%)

62308 (83.57%)
7582 (10.17%)
4667 (6.26%)

0.4997
0.9805
0.3168

1.17
0.04
1.71

0.90 + 1.47
12.73 + 7.51
16 (0.46%)
1517 (43.88%)

1.01 + 1.60
10.53 + 6.64
947 (1.27%)
20920 (28.06%)

<0.0001
<0.0001
<0.0001
<0.0001

7.25
31.04
8.72
33.43

2528 (73.13%)
1818 (52.59%)
376 (10.88%)
589 (17.04%)
935 (27.05%)
277 (8.01%)
201 (5.81%)
294 (8.50%)
161 (4.66%)
161 (4.66%)
95 (2.75%)
6 (0.17%)
25 (0.72%)
22 (0.64%)
2 (0.06%)
0

45320 (60.79%)
36749 (49.29%)
12231 (16.40%)
4601 (6.17%)
7177 (9.63%)
2887 (3.87%)
915 (1.23%)
1812 (2.43%)
807 (1.08%)
279 (0.37%)
1144 (1.53%)
132 (0.18%)
627 (0.84%)
409 (0.55%)
40 (0.05%)
1 (0%)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.9620
0.4570
0.4959
0.9170
0.8295

26.47
6.60
16.16
34.43
46.20
17.58
25.08
26.96
21.53
27.61
8.39
0.08
1.34
1.14
0.18
0.52

0.36 + 0.98
5.02 + 6.93

0.39 + 0.93
5.48 + 5.43

0.0270
<0.0001

3.93
6.46

a

Pooled or Satterthwaite p-value for t-test based on test of equal variances
Not included in the propensity score model since there are zero cases
Abbreviation used: d/o; disorder
b
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Propensity scores for off-label users and non-users were computed using logistic
regression. Figures 8a and 9a illustrate the distribution of the propensity scores in the two groups
before matching using the box-plot and histogram techniques and show overlapping distributions
indicating that the common support assumption holds true. The mean scores are significantly
different among users and non-users as seen by the Kolmogorov-Smirnov two sample test
(p<0.0001) and hence matching between the groups was done to remove baseline differences.
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1: AAPs Users; 0: Non-Users

Figure 8a: Distribution of propensity scores before matching

1: AAPs Users; 0: Non-Users

Figure 8b: Distribution of propensity scores after matching
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1: AAPs Users; 0: Non-Users

Figure 9a: Distribution of propensity scores before matching – Boxplot

1: AAPs Users; 0: Non-Users

Figure 9b: Distribution of propensity scores after matching – Boxplot
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Post-match study groups: After matching, no difference was found among the means of
the propensity scores between the cohorts (p=1.0000). Figures 8b and 9b also visually illustrate
that the distribution of scores were very similar across the two groups after matching. The number
of beneficiaries in the AAPs user and non-user cohort before and after matching is reported in
Table 18.

Table 18. Pre and post-match cohort counts
Frequency

Percent

Cumulative
Frequency

Cumulative
percent

Control

74557

95.57

74557

95.57

Case

3457

4.43

78014

100.00

Control

3438

50.00

3438

50.00

Case

3438

50.00

6876

100.00

Pre

Post

To assess if the propensity score matching process balanced the covariates across the two
groups, absolute standardized differences were calculated (Table 19). All standardized differences
are less than 10%; hence good matches with balanced observed covariates were obtained. The
groups had a mean age of 66 years, comprised mostly white females an average of 13 unique
medications. In addition, majority of beneficiaries had a diagnosis for depression or neurotic
disorders.
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Table 19: Baseline characteristics of off-label cohort post-matching
Variable
Demographic
Age (years)
<65
65-84
>=85
Male
Race
White
Black
Others
Disease Burden
CCI
No. of medications
ESRD
Disability
Mental Health Disorders
Depression
Neurotic
Psychoactive Substance
Mental Retardation
Other Organic Psychoses
Other Mental Disorders
Personality
Dementia
Child and Adolescent
Child Organic Psychoses
Transient Organic Psychoses
Drug Psychoses
Alcoholic Psychoses
Psychosexual
Non-Organic Psychoses
Resource Utilization
Inpatient
Outpatient

AAPs User
(N=3,438)

AAPs Non-User
(N=3,438)

Standardized
Difference (%)

66.29+18.42 (20-101)
1477 (42.96%)
1304 (37.93%)
657 (19.11%)
1130 (32.87%)

66.01+17.44 (21-104)
1516 (44.10%)
1368 (39.79%)
554 (16.11%)
1123 (32.66%)

1.53

2858 (83.13%)
350 (10.18%)
230 (6.69%)

2794 (81.27%)
380 (11.05%)
264 (7.68%)

4.87
2.83
3.83

0.90+1.48
12.70+7.39
16 (0.47%)
1500 (43.63%)

0.98+1.51
13.13+8.04
20 (0.58%)
1549 (45.06%)

4.88
5.54
1.61
2.87

2516 (73.18%)
1804 (52.47%)
376 (10.94%)
572 (16.64%)
925 (26.91%)
273 (7.94%)
199 (5.79%)
290 (8.44%)
150 (4.36%)
151 (4.39%)
92 (2.68%)
25 (0.73%)
22 (0.64%)
6 (0.17%)
2 (0.06%)

2561 (74.49%)
1771 (51.51%)
375 (10.91%)
548 (15.94%)
974 (28.33%)
274 (7.97%)
187 (5.44%)
269 (7.82%)
136 (3.96%)
99 (2.88%)
94 (2.73%)
22 (0.64%)
18 (0.52%)
6 (0.17%)
0

2.98
1.92
0.09
1.89
3.19
0.11
1.52
2.23
2.04
8.09
0.36
1.06
1.53
0
3.41

0.36+0.98
5.02+6.94

0.38+0.88
5.34+6.67

2.71
4.69

73

0.43

Costs: Table 20 presents direct all-cause health care costs for beneficiaries by AAPs use to
treat off-label mental health conditions during the follow-up period. Costs were broken down
based on payers; Medicare costs, out-of-pocket costs by the beneficiary and other payers such as
a private insurance. Medicare followed by beneficiaries paying out-of-pocket paid the largest share
of costs. Beneficiaries had to pay the highest share out-of-pocket for prescriptions and these costs
were higher among the AAPs users as compared to the non-users. Among the total health care
costs, the major cost component among non-users was inpatient (IP) cost but among the AAPs
users it was prescription cost (RX) (Figure 10). Outpatient (OP) costs remained similar in both
cohorts.

Figure 10: Breakdown of direct health care costs through the follow-up period

Out of the 6,876 beneficiaries after matching only 29 beneficiaries (0.4%) had zero total
costs and therefore no measures were undertaken to account for a high number of zero costs in the
analyses. Univariate analyses of total costs showed a right skew distribution with a maximum cost
of $455,000 (Figure 11) and hence both total mean (paired t-test) and median (Wilcoxon SignRank test) costs were reported in Table 20. Of the total beneficiaries, 69 had costs greater than
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$92,500 (99% quantile). Due to the presence of some extreme observations the Sign test was also
reported in Table 21. The Sign test assessed differences in median cost in the absence of extreme
observations. Even though there were no differences in the total mean costs between AAPs users
and non-users (p=0.6112), AAPs non-users had significantly higher inpatient costs of $6,945 per
person versus the $4,841 per person among users (p <0.0001). On the other hand, prescription
costs were significantly higher among the users by approximately $1,700 which would also include
the cost of AAPs. Since the cost data is not normally distributed and may be sensitive to extreme
observations, medians were also reported. Median outpatient costs among non-users were
significantly higher than among users even though no differences were found between mean
outpatient costs.

Figure 11: Distribution of total costs in off-label cohort
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Table 20: Direct all-cause health care costs by payer
Variable
AAPs Non-Users
Outpatient
Medicare
Beneficiary
Other payers
Inpatient
Medicare
Beneficiary
Other payers
Prescription
Medicare
Beneficiary
AAPs Users
Outpatient
Medicare
Beneficiary
Other payers
Inpatient
Medicare
Beneficiary
Other payers
Prescription
Medicare
Beneficiary

Mean
($)

Lower
95% CI

Upper
95% CI

Median
($)

Minimum
($)

Maximum
($)

2,117
588
15

1,953
546
3

2,282
629
27

683
206
0

0
0
0

89,071
17,595
12,744

6,295
539
111

5,678
494
-80

6,912
583
303

0
0
0

0
0
0

358,363
51,147
335,446

3,256
880

3,059
854

3,454
906

1,915
687

0
0

125,953
5,548

2,056
574
14

1,893
531
2

2,219
617
26

620
182
0

0
0
0

61,586
16,608
18,796

4,412
395
34

3,954
358
4

4,869
432
65

0
0
0

0
0
0

218,776
44,667
38,259

4,855
1,066

4,695
1,040

5,015
1,092

3,739
896

25
12

86,396
6,378

Abbreviation used: CI, Confidence interval
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Table 21: Mean all-cause health care costs for AAPs users and non-users
Variable

Non-Users

Outpatient

Mean
($)
2,720

Median
($)
897

Inpatient

6,945

Prescription

Users
SD

SD

p-value
Sign

WSR

0.0013

0.0181

6,129

Mean
($)
2,644

Median
($)
837

6,159

Paired
t-test
0.6112

0

20,238

4,841

0

14,389

<0.0001 <0.0001 <0.0001

4,137

2,630

6,442

5,921

4,742

5,310

<0.0001 <0.0001 <0.0001

Total

13,801

6,389

23,704

13,407

7,979

18,130

0.4373

<0.0001

- Medicare

11,669

4,788

21,335

11,323

6,283

16,614

0.4536

<0.0001 <0.0001

Abbreviation used: SD, Standard Deviation; WSR, Wilcoxon Sign-Rank

Resource Utilization: The descriptive statistics and patterns of RU by beneficiaries using
and those not using AAPs off-label to treat their mental health conditions are reported in Table 22.
In the 12 month follow-up period both users and non-users had an average of six outpatient visits
per year and 13 medications per year with no significant differences among the cohorts (Table 23)
except for the number of medication claims. On the other hand beneficiaries who used AAPs for
off-label treatment had significantly lower number of inpatient visits (p <0.0001) during the
follow-up period. The maximum number of times an AAPs user used an inpatient service was 10
times a year in comparison to the 14 visits by a non-user.
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0.0002

Table 22: Annual health care RU among off-label AAPs users and non-users
Variable
AAPs Non-Users
Outpatient visits
Inpatient visits
Medication claims
Unique medications
AAPs Users
Outpatient visits
Inpatient visits
Medication claims
Unique medications

Mean

Lower 95% CI

Upper 95% CI

Min

Max

6.39
0.58
67.50
13.08

6.12
0.54
65.85
12.82

6.66
0.61
69.14
13.34

0
0
0
0

103
14
428
51

6.41
0.41
84.78
13.22

6.11
0.38
83.10
12.97

6.71
0.45
86.46
13.46

0
0
2
1

128
10
596
54

Abbreviation used: CI, Confidence interval; Min, Minimum; Max, Maximum

Table 23: Differences in RU between off-label AAPs users and non-users
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

Difference
(Non-Users-Users)
-0.02
0.16
-17.28
-0.14

SD
12.06
1.47
67.74
10.46

Abbreviation used: CI, Confidence interval; SD, Standard Deviation
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Lower
95% CI
-0.42
0.11
-19.55
-0.49

Upper
95% CI
0.38
0.21
-15.02
0.21

p-value
0.2106
<0.0001
<0.0001
0.4445

Logistic regression analyses reported in Table 24 showed that AAPs users had 34% lower
odds than non-users to have an inpatient visit (p <0.0001). Among the AAPs users only 24% had
at least one inpatient visit while at least 32% had an inpatient visit among the non-users. More than
80% of both users and non-users had at least one outpatient visit during the follow-up period.

Table 24: Odds ratios of RU between off-label AAPs users and non-users
Variable

Non-User
(%)

User
(%)

Lower
95% CI

Upper
95% CI

p-value

Non-User=Ref

OR

Outpatient visits

2869 (83.4)

2816 (81.91)

0.896

0.79

1.017

0.0891

Inpatient visits

1101 (32.02)

831 (24.17)

0.661

0.592

0.738

<0.0001

Medication use

3388 (98.55)

3438 (100.00)

*

Abbreviation used: CI, Confidence interval; OR, Odds Ratio
* Regression not done since 100% medication use in user cohort
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Specific Aim IIIB: Compare mental health RU and costs between Medicare beneficiaries
using AAPs and those not using AAPs for off-label treatment of mental health conditions.

Costs: Beneficiaries in the AAPs user cohort had higher total mental health costs during
the follow-up period (Table 25). The mean total costs among AAPs users were $3,665 versus
$1,297 among the non-users (p <0.0001). Prescription costs and outpatient costs were higher
among the AAPs users as compared to non-users but no differences were seen among inpatient
costs. Majority of the costs were attributed to prescription costs which were $2,349 per AAPs
user and $282 per non-user (p<0.0001). Of the five AAPs of interest, risperidone contributed
least to the prescription costs ($397 per beneficiary) while quetiapine contributed the most
($3562 per beneficiary) followed by aripiprazole and olanzapine ($2,769 per beneficiary and
$2,478 per beneficiary respectively).
Table 25: Mean mental health costs among AAPs users and non-users
Variable
Outpatient
Inpatient
Prescription
Total
- Medicare

Non-Users
Mean ($)
SD
297
1,917
719
3,596
282
542
1,297
4,278
1,086
3,838

Users
Mean ($)
461
854
2,349
3,665
3,162

SD
2,378
4,019
2,311
5,211
4,655

Difference ($)

p-value

-165
-135
-2,068
-2,368
-2,076

0.0017
0.1314
<0.0001
<0.0001
<0.0001

Abbreviation used: SD, Standard Deviation

Resource Utilization: The mean number of outpatient and inpatient visits and medications
used are described in Table 26. In the 12 month follow-up period users had an average of more
than one outpatient visit per year. About 30% of AAPs users had at least one outpatient visit during
the year versus only 23% of non-users (Table 27). Regression analyses showed that the odds of
having an outpatient visit among AAPs users was significantly higher as compared to non-users
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(OR = 1.55, p <0.0001). No difference was found in the mean number of mental health inpatient
visits between the groups (Table 26) and approximately 7% of beneficiaries had at least one
inpatient visit over the period of one year (Table 27). AAPs users also had significantly higher
number of medications and medication claims compared to non-users (p<0.0001).
Table 26: Mean annual mental health RU
Variable
Mean
Outpatient visits
Inpatient visits
Medication claims
Unique medications

0.61
0.08
6.97
1.05

Non-Users
Lower
Upper
95% CI 95% CI
0.54
0.67
0.07
0.09
6.68
7.25
1.01
1.08

Mean
1.06
0.09
21.89
2.48

Users
Lower
95% CI
0.94
0.08
21.47
2.44

p-value
Upper
95% CI
1.17
0.11
22.31
2.52

<0.0001
0.0769
<0.0001
<0.0001

Abbreviation used: CI, Confidence interval

Table 27: Odds ratios of mental health RU
Variable

Non-User
(%)

User
(%)

OR
Non-User=Ref

Lower
95% CI

Upper
95% CI

p-value

Outpatient visits

775 (22.54)

1059 (30.80)

1.553

1.39

1.735

<0.0001

Inpatient visits

226 (6.57)

257 (7.48)

1.156

0.956

1.397

0.1348

Medication use

2202 (64.05)

3438 (100.00)

*

Abbreviation used: CI, Confidence interval; OR, Odds Ratio
* Regression not done since 100% medication use in user cohort
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5.3 Specific Aim IV

Specific Aim IV A: To compare all-cause resource utilization and costs between Medicare
beneficiaries using AAPs and those not using AAPs for on-label treatment of mental health
conditions.
Pre-match study groups: For this aim, the study groups identified before matching were
on-label AAPs user cohort (N=1,219) and on-label AAPs non-user cohort (N=2,442). The
characteristics of these beneficiaries are described in Table 28 and the cohorts were different across
multiple covariates. The typical AAPs user was a younger white male with fewer comorbid
conditions but higher chances of disability and having a diagnosis for schizophrenia or bipolar
disorder as compared to the typical non-user. The cohorts also differed in their RU with AAPs
users having lower numbers of inpatient and outpatient visits the prior year.
After the propensity scores were computed using logistic regression model, the scores were
plotted and the overlapping graphs indicated that the common support assumption held true
(Figures 10a and 11a). The Kolmogorov-Smirnov two sample test showed that the propensity
scores were significantly different among the users and non-users (p<0.0001).
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Table 28: Baseline characteristics of on-label cohort pre-matching
Variable

AAPs User
(N=1,219)

AAPs Non-User
(N=2,442)

p-valuea

Demographic
Age (years)
51.70 +15.70
66.14+17.78
<0.0001
Male
763 (62.59%)
1160 (47.50%)
<0.0001
Race
White
833 (68.33%)
1839 (75.31%)
<0.0001
Black
269 (22.07%)
428 (17.53%)
0.0010
Others
117 (9.60%)
175 (7.17%)
0.0105
Disease Burden
CCI
0.32+0.91
0.74+1.41
<0.0001
No. of medications
7.17+4.96
7.64+5.97
0.0108
ESRD
3 (0.25%)
28 (1.15%)
0.00051
Disability
960 (78.75%)
1018 (41.69%)
<0.0001
Mental Health Disorders
Schizophrenia
1024 (84.00%)
1836 (75.18%)
0.0011
Bipolar Disorder
454 (37.24%)
777 (31.82%)
<0.0001
Resource Utilization
Inpatient
0.05+0.29
0.23+0.70
<0.0001
Outpatient
2.25+4.35
3.87+6.30
<0.0001
a
Pooled or Satterthwaite p-value for t-test based on test of equal variances

Standardized
Difference (%)
86.07
30.69
15.55
11.41
8.78
34.90
8.67
10.84
81.82
22.01
11.43
32.40
29.93

Post-match study groups: After the user and non-user cohorts were matched no difference
was found in the means of the propensity scores (p=1.0000). Figures 12b and 13b illustrate that
the distribution of the scores are very similar between the two groups after matching. The total
numbers of matched pairs are reported in Table 29. A total of 981 matched pairs were obtained for
this aim.
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Table 29: Pre and post-match cohort counts

Frequency

Percent

Cumulative
Frequency

Cumulative
percent

Control

2442

66.70

2442

66.70

Case

1219

33.30

3661

100.00

Control

981

50.00

981

50.00

Case

981

50.00

1962

100.00

Pre

Post
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1: AAPs Users; 0: Non-Users

Figure 12a: Distribution of propensity scores before matching

1: AAPs Users; 0: Non-Users

Figure 12b: Distribution of propensity scores after matching
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1: AAPs Users; 0: Non-Users

Figure 13a: Distribution of propensity scores before matching – Boxplot

1: AAPs Users; 0: Non-Users

Figure 13b: Distribution of propensity scores after matching – Boxplot
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The absolute standardized differences after matching were calculated and reported in Table
30. All the differences were less than 10% and hence all the covariates were appropriately balanced
across the user and non-user cohort. The groups had a mean age of 54 years, comprised mostly of
white males with disability and approximately seven unique medications the previous year with
majority of beneficiaries having a diagnosis for schizophrenia and two outpatient visits per year.

Table 30: Baseline characteristics of on-label cohort post-matching
Variable

AAPs User
(N=981)

Demographic
Age (years)
54.47+15.53 (21-98)
Male
589 (60.04%)
Race
White
677 (69.01%)
Black
217 (22.12%)
Others
87 (8.87%)
Disease Burden
CCI
0.36+0.98
No. of medications
7.02+4.79
ESRD
3 (0.31%)
Disability
722 (73.60%)
Mental Health Disorders
Schizophrenia
797 (81.24%)
Bipolar Disorder
345 (35.17%)
Resource Utilization
Inpatient
0.06+0.30
Outpatient
2.45+4.69
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AAPs Non-User
(N=981)

Standardized
Difference (%)

54.17+16.68 (21-102)
573 (58.41%)

1.85
3.32

658 (67.07%)
223 (22.73%)
100 (10.19%)

4.15
1.47
4.51

0.32+0.83
6.83+6.14
2 (0.20%)
728 (74.21%)

4.83
3.46
2.02
1.39

789 (80.43%)
345 (35.17%)

2.07
0

0.07+0.38
2.24+3.86

2.37
4.79

Costs: The descriptive statistics of all-cause health care costs of beneficiaries using and not
using AAPs to treat FDA approved conditions are reported in Table 31. Among non-users the
highest cost component was inpatient (IP) costs but among AAPs users it was prescription (Rx)
costs (Figure 14). Outpatient (OP) costs were consistent across the groups with non-users having
22% of their costs coming from outpatient services. Among users, Medicare paid a mean of $5,052
per beneficiary in a year and beneficiaries paid an average of $557 per person out-of-pocket. As
with the off-label cohort, prescription costs were the major out-of-pocket costs for beneficiaries.

Figure 14: Breakdown of health care costs by component

Only 113 (5%) of the 1,962 beneficiaries had zero total costs and the cost distribution had
a right skew distribution. The maximum total cost per beneficiary for the year was $227,900
(Figure 15) but 99% of beneficiaries had a mean total cost less than $53,000 per beneficiary. The
mean and median total costs are reported in Table 32. Mean total costs were found to be
significantly higher in AAPs users ($7,929) as compared to non-users ($5,402) with a p <0.0001.
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Even though users had higher mean prescription costs, they had a significantly lower mean
inpatient cost of $1,012 per beneficiary versus $2,257 per beneficiary among non-users
(p=0.0019). No differences were found in outpatient costs and these results were robust even in
the absence of extreme observations (Table 32).

Figure 15: Distribution of total costs among beneficiaries in on-label cohort

89

Table 31: Direct all-cause health care costs by payer
Variable
AAPs Non-Users
Outpatient
Medicare
Beneficiary
Other payers
Inpatient
Medicare
Beneficiary
Other payers
Prescription
Medicare
Beneficiary
AAPs Users
Outpatient
Medicare
Beneficiary
Other payers
Inpatient
Medicare
Beneficiary
Other payers
Prescription
Medicare
Beneficiary

Mean ($)

Lower
95% CI

Upper
95% CI

Median
($)

Minimum
($)

Maximum
($)

881
282
7

679
207
-4

1,083
357
17

131
24
0

0
0
0

51,434
24,101
4,883

2,083
159
16

1,412
124
-15

2,754
193
46

0
0
0

0
0
0

212,141
8,781
15,258

1,582
392

1,388
358

1,777
426

696
185

0
0

51,051
4,282

993
282
33

730
212
-5

1,256
353
71

116
20
0

0
0
0

68,032
19,084
17,069

913
87
11

596
66
-11

1,231
109
33

0
0
0

0
0
0

86,806
2,602
11,021

5,052
557

4,794
525

5,309
589

3,938
411

63
3

26,055
4,558

Abbreviation used: CI, Confidence interval
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Table 32: Mean all-cause health care costs for on-label AAPs users and non-users
Variable

Non-Users

Outpatient

Mean Median
($)
($)
1,170
171

Inpatient

2,257

Prescription

Users
SD
4,356

Mean Median
($)
($)
1,308
164

0

11,160

1,012

1,975

953

3,448

Total

5,402

1,858

- Medicare

4,547

1,407

p-value
SD

Sign

WSR

5,350

Paired
t-test
0.5311

0.5803

0.6459

0

5,338

0.0019

0.0109

0.001

5,609

4,519

4,324

<0.0001 <0.0001 <0.0001

13,420

7,929

5,660

9,073

<0.0001 <0.0001 <0.0001

12,307

6,958

4,784

8,011

<0.0001 <0.0001 <0.0001

Abbreviation used: SD, Standard Deviation; WSR, Wilcoxon Sign-Rank

Resource utilization: The pattern of RU by beneficiaries using AAPs in the presence of
schizophrenia and bipolar conditions have been described in Table 33. Both users and non-users
had an average of almost four outpatient visits during the year and did not differ significantly
(p=0.4826) (Table 34). Users had a significantly fewer inpatient visits during the year (p=0.0008).
There were non-users who had to use the inpatient services up to nine times during the year while
the maximum number of inpatient stays a AAPs user had was only four times in the year. Users
were prescribed more medications during the year in comparison to their non-user counterparts (7
vs 6 respectively) and also had higher number of medication claims.
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Table 33: Annual health care RU among on-label AAPs users and non-users
Variable
AAPs Non-Users
Outpatient visits
Inpatient visits
Medication claims
Unique medications
AAPs Users
Outpatient visits
Inpatient visits
Medication claims
Unique medications

Mean

Lower 95% CI

Upper 95% CI

Min

Max

3.80
0.17
37.89
6.86

3.40
0.13
35.61
6.47

4.19
0.21
40.17
7.26

0
0
0
0

64
9
221
37

3.85
0.09
54.99
7.60

3.46
0.07
52.59
7.28

4.23
0.11
57.38
7.92

0
0
1
1

58
4
245
30

Abbreviation used: CI, Confidence interval; Min, Minimum; Max, Maximum

Table 34: Differences in RU between on-label AAPs users and non-users
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

Difference
(Users-Non Users)
-0.05
0.08
-17.10
-0.73

SD
8.58
0.75
51.06
7.82

Abbreviation used: CI, Confidence interval; SD, Standard Deviation
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Lower
95% CI
-0.5906
0.0333
-20.2963
-1.2249

Upper
95% CI
0.4846
0.1277
-13.8974
-0.2451

p-value
0.4826
0.0008
<0.0001
0.0033

Results of the conditional logistic regression models are reported in Table 35. AAPs users
had 36% lower odds of having an inpatient visit during the year compared to non-users (p=0.0069)
and had the same odds as a non-user for having an outpatient visit (p=0.1249). More than 10% of
non-users had at least one inpatient visit during the year versus only 7% of the AAPs users. Even
though no differences were found in the mean number of outpatient visits between the groups,
there was a slightly higher number of users (65%) who had at least one outpatient visit when
compared to the non-users (62%).

Table 35: Adjusted odds ratios of RU between on-label AAPs users and non-users
Variable

User
(%)
638 (65.04)

Non-User=Ref

Outpatient visits

Non-User
(%)
606 (61.77)

Inpatient visits

102 (10.40)

68 (6.93)

Medication use

842 (85.83)

*

Abbreviation used: CI, Confidence interval; OR, Odds Ratio
* Regression not done since 100% medication use in user cohort
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OR

Upper
95% CI
1.4

p-value

1.159

Lower
95% CI
0.96

0.642

0.466

0.886

0.0069

0.1249

Specific Aim IVB: Compare mental health RU and costs between Medicare beneficiaries using
AAPs and those not using AAPs for on-label treatment of mental health conditions.

Costs: AAPs users were found to have significantly higher mean total, prescription and
inpatient costs (Table 36). The mean total costs among AAPs users were $4,959 versus only $744
among non-users (p <0.0001). Medicare was paying an average of $4,605 per AAPs user per year
to cover mental health costs versus only paying $640 per non-user per year. Inpatient and
prescription costs were also found to be higher among AAPs users as compared to non-users but
no differences were found for outpatient costs. Prescription cost was the major cost component
among the users. Among the AAPs agents, risperidone cost the least at approximately $613 per
beneficiary, while quetiapine cost $6,434 per beneficiary followed by olanzapine and aripiprazole
at $5,644 per beneficiary and $3,402 per beneficiary respectively.
Table 36: Mean mental health costs among AAPs users and non-users
Variable
Outpatient
Inpatient
Prescription
Total
- Medicare

Non-Users
Mean ($)
SD
197
129
418
744
640

1,649
1,650
931
2,539
2,154

Users
Mean ($)
369
370
4,221
4,959
4,605

Abbreviation used: SD, Standard Deviation
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Difference ($)

p-value

-172

0.0782
0.0117
<0.0001
<0.0001
<0.0001

SD
2,563
2,478
3,999
5,555
5,129

-241
-3,802
-4,215
-3,966

Resource Utilization: The pattern of mental health RU is described in Table 37. AAPs
users had significantly higher RU as compared to non-users. Users were prescribed an average of
two psychotherapeutic medications and filled approximately 21 prescriptions in the year while
non-users had an average of one medication per year and had an average of only seven claims per
year. Approximately 27% of users had at least one outpatient visit during the year as compared
with only 18% of non-users (Table 38). Users had 1.68 times and 2.75 times the odds of non-users
to have an outpatient and inpatient visit respectively during the follow-up period.

Table 37: Mean annual mental health RU among AAPs users and non-users
Variable
Mean
Outpatient visits
Inpatient visits
Medication claims
Unique medications

1.09
0.01
7.74
0.88

Non-Users
Lower
Upper
95% CI 95% CI
0.83
1.34
0.01
0.02
7.04
8.43
0.82
0.94

Mean
1.20
0.04
21.41
2.12

Users
Lower
95% CI
0.98
0.03
20.56
2.05

p-value
Upper
95% CI
1.42
0.06
22.26
2.19

0.0105
0.0009
<0.0001
<0.0001

Abbreviation used: CI, Confidence interval

Table 38: Adjusted odds ratios of mental health RU
Variable

Non-User
(%)

User
(%)

OR
Non-User=Ref

Lower
95% CI

Upper
95% CI

p-value

Outpatient visits

177 (18.04)

263 (26.81)

1.683

1.35

2.098

<0.0001

Inpatient visits

12 (1.22)

33 (3.36)

2.75

1.42

5.324

0.0027

Medication use

536 (54.64)

981 (100.00)

*

Abbreviation used: CI, Confidence interval; OR, Odds Ratio
* Regression not done since 100% medication use in user cohort
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5.4 Specific Aim V
Specific Aim V: Evaluate differences in RU and associated costs in Medicare
beneficiaries using AAPs and those not using AAPs to treat specific mental health
conditions.
Depression: Beneficiaries with a diagnosis of depression and no other mental health
conditions were identified. Before matching the beneficiaries with depression who used AAPs in
their treatment and those who did not differed on all baseline characteristics. After matching, 544
pairs with balanced covariates were obtained as reported in Table 39. The typical beneficiary with
depression was a 67 year old white female prescribed 13 medications with less than one inpatient
and four outpatient visits during the year.
Table 39: Characteristics of beneficiaries with depression before and after matching
Variable

Demographic
Age (%)
Mean (years)
<65
65-84
>=85
Sex (%)
Male
Race (%)
White
Black
Others
Disease Burden
CCI (mean)
No. of meds (mean)
ESRD (%)
Disability (%)
RU
Inpatient (mean)
Outpatient (mean)

Pre-match

Post-match

User
N=545

Non-User
N=18,995

ASD
(%)

User
N=544

Non-User
N=544

ASD
(%)

67.93+16.67
37.80
46.42
15.78

71.17+13.32
21.67
65.18
13.15

21.47

67.95+16.68
37.68
46.51
15.81

67.28+14.89
38.60
49.63
11.76

4.24

32.84

26.46

14.01

32.72

34.19

3.12

75.96
13.21
10.83

83.97
8.87
7.15

20.12
13.88
12.86

75.92
13.24
10.85

75.55
11.95
12.50

0.86
3.88
5.15

0.69+1.40
12.39+7.28
0.18
39.08

0.97+1.60
10.69+6.30
1.35
22.45

18.32
25.1
13.42
36.64

0.69+1.40
12.33+7.11
0.18
38.97

0.82+1.30
12.87+7.03
0.74
40.81

9.91
7.64
8.16
3.75

0.17+0.60
4.00+7.02

0.31+0.78
5.29+7.22

19.79
17.78

0.17+0.60
4.01+7.03

0.23+0.61
4.07+5.27

9.83
0.98

Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference
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Among the 544 patients on AAPs, 433 (80%) had claims for antidepressants in the previous
year. This could be indicative of patients who are resistant to treatment or relapsing after a
successful course on antidepressants. In beneficiaries with a diagnosis for depression the mean
total direct costs were $11,545 among AAPs non-users which was significantly higher than the
mean costs of $10,804 among AAPs users (p=0.0173) (Table 40). Non-users had a greater number
of inpatient visits during the year and also had higher inpatient costs compared to AAPs users. On
the other hand there were no differences in mean number of outpatient visits and mean outpatient
costs by AAPs use (Table 41). Even though it was expected that users would be prescribed more
medications, both groups were using an average of 13 medications during the follow up year but
the costs were significantly greater among the users ($6,152 vs $4,145).

Table 40: Mean all-cause health care costs of beneficiaries with depression
Variable
Outpatient
Inpatient
Prescription
Total

AAPs Non-Users
Mean ($)
SD
2,145
5,020
5,255
23,847
4,145
7,511
11,545
26,485

AAPs Users
Mean ($)
SD
2,123
5,699
2,528
12,951
6,152
6,550
10,804
17,376

p-value
0.9442
0.0201
<0.0001
0.0173

Abbreviation used: SD, Standard Deviation

Table 41: Mean all-cause RU in beneficiaries with depression
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD
4.84
6.34
0.32
0.78
61.99
45.85
12.64
7.09

Abbreviation used: SD, Standard Deviation
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AAPs Users
Mean
SD
5.18
9.01
0.17
0.58
82.29
55.01
12.80
7.36

p-value
0.4452
0.0005
<0.0001
0.6727

Anxiety and other neurotic disorders: Beneficiaries with ICD-9-CM diagnosis code 300
including disorders such as anxiety, phobias and obsessive compulsive disorder were identified.
The balance between the covariates before and after matching are reported in Table 42. After
matching 126 pairs were identified with balanced covariates. Beneficiaries with anxiety or other
neurotic disorders were typically 65 years, white, female with mean CCI score of 0.6, 11 unique
medications and three outpatient visits in a year.

Table 42: Characteristics of beneficiaries with anxiety and neurotic disorders before and after
matching
Variable

Pre-match
User
N=126

Demographic
Age (%)
Mean (years)
<65
65-84
>=85
Sex (%)
Male
Race (%)
White
Black
Others
Disease Burden
CCI (mean)
No. of meds (mean)
ESRD (%)
Disability (%)
RU
Inpatient (mean)
Outpatient (mean)

Non-User
N=12,812

65.38+18.02 73.16+11.86
43.65
13.98
41.27
72.31
15.08
13.71

Post-match
ASD
(%)

User
N=126

Non-User
N=126

ASD
(%)

51.01

65.38+18.02
43.65
41.27
15.08

65.53+15.80
40.48
50.00
9.52

0.89

36.51

23.24

29.29

36.51

33.33

6.66

84.13
6.35
9.52

85.47
8.35
6.17

3.75
7.68
12.48

84.13
6.35
9.52

84.92
4.76
10.32

2.19
6.93
2.65

0.67+1.48
11.43+6.98
0
43.65

0.77+1.37
9.56+5.89
0.69
14.59

6.76
28.88
11.76
67.52

0.67+1.48
11.43+6.98
0
43.65

0.63+1.20
11.37+7.18
0
42.86

2.93
0.78
0
1.60

0.21+0.73
3.23+4.32

0.27+0.70
4.60+6.34

8.29
25.22

0.21+0.73
3.23+4.32

0.26+0.62
3.03+3.89

7.00
4.83

Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference
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In beneficiaries with diagnosis for anxiety or other neurotic disorders the mean total direct
costs were $7,250 among AAPs users which was significantly higher than the mean costs of $5,966
among the AAPs non-users (p=0.0397) as shown in Table 43. Unlike in depression, non-users did
not differ in their mean inpatient visits or inpatient costs from users. Even though the groups did
not differ significantly in their mean outpatient visits or number of medications in the follow up
period (Table 44), the costs did differ significantly. AAPs users had higher prescription costs
($5,474) in comparison to non-users ($3,030) but had significantly lower outpatient costs ($947
vs $1,548).

Table 43: Mean all-cause costs of beneficiaries with anxiety and neurotic disorders
Variable
Outpatient
Inpatient
Prescription
Total

AAPs Non-Users
Mean ($)
SD
1,548
2,560
1,388
3,963
3,030
4,348
5,966
7,480

AAPs Users
Mean ($)
SD
947
1,967
828
4,087
5,474
7,429
7,250
8,514

p-value
0.0253
0.2083
0.0011
0.0397

Abbreviation used: SD, Standard Deviation

Table 44: Mean all-cause RU in beneficiaries with anxiety and neurotic disorders
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD
3.86
4.70
0.16
0.41
50.48
36.01
10.85
7.23

Abbreviation used: SD, Standard Deviation
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AAPs Users
Mean
SD
3.17
4.95
0.09
0.44
71.02
47.23
11.52
6.18

p-value
0.2105
0.1503
<0.0001
0.4252

Dementia: Since there were very few beneficiaries who had dementia in the absence of
other mental health conditions, all beneficiaries who had a diagnosis for dementia were included
even if they had other mental health conditions. In order to account for the presence of other mental
health conditions, was controlled for in the matching. After matching, 279 pairs were identified
but the groups were not balanced across all covariates (Table 45). Baseline inpatient RU and the
presence of other mental disorders were not balanced across groups and hence these variables were
further controlled using GLM regression analyses.
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Table 45: Characteristics of beneficiaries with dementia before and after matching
Variable
Pre-match
Post-match
User
N=294
Demographic
Age (%)
Mean (Years)
81.79+9.5
<65 (%)
4.76
65-84
50.68
>=85
44.56
Sex (%)
Male
20.75
Race (%)
White
82.99
Black
12.24
Others
4.76
Disease Burden
CCI (mean)
1.74+1.73
No. of meds (mean)
12.82+6.4
ESRD (%)
0.34
Disability (%)
4.76
Resource Utilization
Inpatient (mean)
0.58+1.15
Outpatient (mean)
6.07+7.99
Mental Health Disorders (%)
Depression
67.69
Neurotic
42.86
Psychoactive Substance
5.44
Mental Retardation
2.72
Other Organic Psychoses
69.39
Other Mental Disorders
10.20
Personality
3.40
Child and Adolescent
4.42
Child Organic Psychoses
0.34
Transient Organic
4.76
Psychoses
Psychosexual
0
Drug Psychoses
0.34
Alcoholic Psychoses
0.68
Non-Organic Psychoses
0.34

Non-User
N=1,812

ASD
(%)

User
N=279

Non-User
N=279

ASD
(%)

82.95+8.5
2.98
50.72
46.30

12.88

82.38+8.7
3.58
50.18
46.24

82.32+8.4
3.23
56.99
39.78

0.66

21.58

2.03

20.79

22.58

4.35

80.35
13.52
6.13

6.83
3.81
6.01

82.80
12.19
5.02

82.80
12.54
4.66

0
1.09
1.67

1.48+1.70
10.45+6.3
1.21
3.04

15.40
37.35
9.96
8.93

1.70+1.71
12.52+6.1
0.36
3.58

1.81+1.81
12.56+7.2
0.36
3.58

6.30
0.59
0
0

0.52+1.02
6.53+9.23

5.62
5.41

0.57+1.16
6.07+8.10

0.71+1.13
5.75+6.84

12.22
4.25

49.94
33.55
5.30
1.32
49.83
4.91
1.05
0.77
0.06

36.65
19.23
0.64
9.93
40.67
20.12
16
23.1
6.42

66.67
41.22
5.02
1.43
68.1
9.68
2.15
2.15
0.36

67.03
41.94
4.30
1.43
70.25
6.45
1.08
2.51
0

0.76
1.45
3.40
0
4.66
11.87
8.54
2.38
8.48

3.97

3.86

4.30

3.58

3.68

0.06
0.77
0.77
0.17

3.32
5.82
1.09
3.48

0
0.36
0.72
0.36

0
0
0.36
0.36

0
8.48
4.90
0

Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference
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In beneficiaries with diagnosis for dementia in the presence of other mental health
conditions the mean total direct costs were not significantly different among AAPs non-users
($18,803) and AAPs users ($16,873) (Table 46). Non-users had a significantly greater number of
inpatient visits during the year (p=0.0490) and had higher inpatient costs ($11,613 for non-users
vs. $8,254 for users). On the other hand there were no differences in mean number of outpatient
visits (Table 47) and mean outpatient costs by AAPs use. On average beneficiaries with dementia
were prescribed 13 medications per year but AAPs users ($5,018) had significantly higher
prescription costs than non-users ($3,601).

Table 46: Mean all-cause health care costs of beneficiaries with dementia
Variable
Outpatient
Inpatient
Prescription
Total

AAPs Non-Users
Mean ($)
SE
3,648
348
11,613
1,322
3,601
161
18,803
1,335

AAPs Users
Mean ($)
SE
3,528
344
8,254
1,153
5,018
224
16,873
1,265

p-value
0.8050
0.0490
<0.0001
0.2880

Abbreviation used: SD, Standard Deviation

Table 47: Mean all-cause RU in beneficiaries with dementia
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SE
8.32
0.57
0.99
0.08
75.31
2.44
13.02
0.36

Abbreviation used: SD, Standard Deviation
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AAPs Users
Mean
SE
8.21
0.57
0.72
0.07
88.60
2.89
13.36
0.37

p-value
0.887
0.0170
<0.0001
0.5170

Schizophrenia: Beneficiaries with a diagnosis of schizophrenia and no other mental health
conditions were identified. Before matching the beneficiaries with a schizophrenia diagnosis had
different baseline characteristics based on their AAPs use. Beneficiaries prescribed AAPs were a
younger cohort with mean age of 53 years as compared to the non-users with a mean age of 70
years. After matching, 622 pairs of beneficiaries with schizophrenia and no other mental health
conditions were identified (Table 48). The typical beneficiary with schizophrenia was a 56-yearold white male with a mean CCI score of 0.32, prescribed six medications and an average of two
outpatient visits during the year.

Table 48: Characteristics of beneficiaries with schizophrenia before and after matching
Variable
User
N=765
Demographic
Age (%)
Mean (years)
<65
65-84
>=85
Sex (%)
Male
Race (%)
White
Black
Others
Disease Burden
CCI (mean)
No. of meds (mean)
ESRD (%)
Disability (%)
RU
Inpatient (mean)
Outpatient (mean)

Pre-match
Non-User
N=1,665

ASD
(%)

User
N=622

Post-match
Non-User
N=622

ASD
(%)

52.90+16.02
75.56
21.05
3.40

69.81+17.10
33.27
45.11
21.62

102.04

56.10+15.52
70.10
25.72
4.18

55.89+16.29
69.94
25.56
4.50

1.31

67.97

47.21

42.98

64.15

65.27

2.35

64.44
25.23
10.33

72.13
19.58
8.29

16.58
13.58
7.02

64.47
25.40
10.13

63.67
25.88
10.45

1.67
1.1
1.06

0.27+0.77
6.55+4.63
0.26
76.21

0.85+1.53
7.76+6.04
1.62
33.63

48.12
22.53
14.12
94.67

0.32+0.83
6.56+4.64
0.32
70.74

0.32+0.78
6.40+6.01
0.32
70.26

0.20
3.08
0
1.06

0.05+0.28
2.11+4.46

0.27+0.78
4.24+6.89

38.70
36.73

0.06+0.31
2.35+4.86

0.05+0.29
2.42+5.36

3.75
1.38

Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference
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In beneficiaries with diagnosis for schizophrenia the mean total direct costs were $4,999
among AAPs non-users which was significantly lower than the mean costs of $7,989 among the
AAPs users (p<0.0001) (Table 49). Even though the groups did not differ in their outpatient and
inpatient costs AAPs users had a significantly higher prescription costs ($5,753) which was the
major component of total all-cause health care costs. Even though the AAPs users had higher
prescription costs they were prescribed on average seven medications during the year which was
not significantly different from the number of medications non-users were prescribed (p=0.1244)
(Table 50).

Table 49: Mean all-cause health care costs of beneficiaries with schizophrenia
Variable
Outpatient
Inpatient
Prescription
Total

AAPs Non-Users
Mean ($)
SD
1,078
4,011
2,016
12,784
1,905
2,888
4,999
14,452

AAPs Users
Mean ($)
SD
1,227
5,323
1,009
5,780
5,753
4,542
7,989
9,345

p-value
0.5788
0.068
<0.0001
<0.0001

Abbreviation used: SD, Standard Deviation

Table 50: Mean all-cause RU in beneficiaries with bipolar disorder
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD
3.64
6.35
0.13
0.55
36.73
36.17
6.40
5.81

Abbreviation used: SD, Standard Deviation
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AAPs Users
Mean
SD
3.81
6.10
0.09
0.41
53.69
37.87
6.84
4.68

p-value
0.6227
0.1727
<0.0001
0.1244

Bipolar disorder: Beneficiaries with a diagnosis of bipolar disorder and no other mental
health conditions were identified from the population of interest. The AAPs users and non-users
differed significantly in their mean age, mean CCI score, mean number of medications, outpatient
and inpatient visits among others (Table 51). A total of 176 pairs of bipolar patients were identified
after matching and all covariates except race were balanced at baseline, hence race was controlled
for in the regression. The typical beneficiary with bipolar disorder was a 52-year-old white female
with a mean CCI score of 0.4, eight unique medications and two outpatient visits over the baseline
period.
Table 51: Characteristics of beneficiaries with bipolar disorder before and after matching
Variable
User
N=195
Demographic
Age (%)
Mean (Years)
<65 (%)
65-84
>=85
Sex (%)
Male
Race (%)
White
Black
Others
Disease Burden
CCI (mean)
No. of medications
(mean)
ESRD (%)
Disability (%)
Resource Utilization
Inpatient (mean)
Outpatient (mean)

Pre-match
Non-User
N=606

50.00+15.54 59.94+16.59
78.46
51.16
18.97
45.54
2.56
3.3

ASD
(%)

61.78

User
N=176

Post-match
Non-User
N=176

51.68+14.96 51.94+16.75
76.14
76.14
21.02
21.59
2.84
2.27

User
N=195

1.65

43.59

45.54

3.93

46.59

47.73

2.28

82.05
9.23
8.72

85.48
10.07
4.46

9.3
2.83
17.25

82.39
10.23
7.39

86.93
6.25
6.82

12.64
14.5
2.21

0.39+0.97

0.55+1.15

15.27

0.39+1.00

0.40+0.98

1.72

8.54+5.42

7.74+5.80

14.27

7.82+4.80

7.75+6.45

1.2

0
78.97

0.17
52.81

5.75
57.43

0
76.7

0
77.27

0
1.35

0.09+0.32
2.53+3.76

0.15+0.53
3.23+4.83

13.73
16.23

0.09+0.33
2.51+3.83

0.09+0.36
2.45+3.51

0
1.54

Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference
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In beneficiaries with diagnosis for bipolar disorder with no other mental health conditions
the mean total direct costs were significantly higher among the AAPs users ($7,673) as compared
to the non-users ($4,477) (Table 52). This difference in cost was mainly driven by prescription
costs since the inpatient and outpatient costs did not differ by AAPs use. AAPs users had a mean
prescription cost of $5,011 per beneficiary in comparison to $2,321 per non-user (p<0.0001). The
beneficiaries did not differ in their outpatient and inpatient visits (Table 53) but AAPs users were
prescribed on average more unique medications in the follow up period as compared to the nonusers (p<0.0001).

Table 52: Mean all-cause health care costs of beneficiaries with bipolar disorder by AAPs use
Variable
Outpatient
Inpatient
Prescription
Total

AAPs Non-Users
Mean ($)
SE
1,467
283
737
324
2,321
314
4,477
503

AAPs Users
Mean ($)
SE
1,297
244
1,328
458
5,011
683
7,673
865

p-value
0.6460
0.2960
<0.0001
0.0010

Abbreviation used: SD, Standard Deviation

Table 53: Mean all-cause RU in beneficiaries with bipolar disorder
Variable
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SE
3.22
0.34
0.07
0.02
36.00
2.40
7.72
0.42

Abbreviation used: SD, Standard Deviation
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AAPs Users
Mean
SE
3.52
0.37
0.11
0.02
56.00
3.72
9.38
0.51

p-value
0.5530
0.2260
<0.0001
0.0130

5.5 Sensitivity Analyses
1) In Specific Aim III, AAPs users included both existing users and new users of AAPs since
sample size of using only new AAPs users was a concern. In this sensitivity analysis, only
beneficiaries who were new AAPs users were included; that is, any beneficiary with AAPs
prescriptions in 2008 were excluded. The users and non-users were matched and all covariates
were balanced across the two groups. Even though mental health visits and costs remained robust
with AAPs users having more outpatient, prescription and total costs (Table 55), there were some
changes in all-cause costs. Outpatient costs and visits, which were not significantly different
among users and non-users in Specific Aim IIIA, showed that AAPs users had significantly higher
outpatient costs and visits (Table 54). Similarly, inpatient costs between the users and non-users
had no significant differences, which was a change from non-users having more inpatient costs in
Specific Aim IIIA. These results in combination with the mental-health visits may be indicative of
higher RU and costs among new AAPs users.

Table 54: All-cause costs and RU among new off-label AAPs users and non-users
Variable
Cost ($)
Outpatient
Inpatient
Prescription
Total
RU
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD

AAPs Users
Mean
SD

p-value

2,945
8,870
3,798
15,613

6,813
26,197
5,549
29,917

3,675
6,969
5,890
16,534

7,582
16,129
5,659
20,756

0.0010
0.1448
<0.0001
0.4099

6.39
0.58
67.50
13.08

8.16
1.15
49.14
7.82

6.41
0.41
84.78
13.22

8.90
0.96
50.27
7.27

0.0132
0.0390
<0.0001
<0.0001
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Table 55: Mental health costs and RU among new off-label AAPs users and non-users
Variable
Cost ($)
Outpatient
Inpatient
Prescription
Total
RU
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD

AAPs Users
Mean
SD

p-value

183
771
45
1,000

777
3,113
93
3,276

663
1,149
233
2,045

3,143
4,326
220
5,323

<0.0001
0.0226
<0.0001
<0.0001

0.53
0.09
6.88
1.07

1.51
0.33
8.05
1.06

1.36
0.12
18.90
2.61

4.20
0.44
12.44
1.27

<0.0001
0.1323
<0.0001
<0.0001

108

2) In this sensitivity analyses all aripiprazole users were excluded so that any depression AAPs
users in this cohort is truly an off-label user. The users and non-users were matched and all
covariates were balanced across the two groups. As in the previous sensitivity analysis, the mental
health costs and RU remained robust despite the change in the included cohort (Table 57).
Interestingly, in all-cause costs, outpatient, inpatient, prescription, and total costs were now
significantly higher among AAPs non-users (Table 56). In Specific Aim IIIA, only inpatient costs
and prescription costs were higher among non-users while no differences were observed in
outpatient and total costs.

Table 56: All-cause costs and RU among off-label AAPs users and non-users excluding
aripiprazole users
Variable
Cost ($)
Outpatient
Inpatient
Prescription
Total
RU
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD

AAPs Users
Mean
SD

p-value

2,714
7,327
3,933
13,975

5,559
21,752
6,654
24,716

2,506
4,709
5,551
12,766

5,786
13,957
4,999
17,483

0.0030
<0.0001
<0.0001
0.0390

6.39
0.58
67.50
13.08

8.16
1.15
49.14
7.82

6.41
0.41
84.78
13.22

8.90
0.96
50.27
7.27

0.0368
<0.0001
<0.0001
0.3937
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Table 57: Mental health costs and RU among off-label AAPs users and non-users excluding
aripiprazole users
Variable
Cost ($)
Outpatient
Inpatient
Prescription
Total
RU
Outpatient visits
Inpatient visits
Medication claims
Unique medications

AAPs Non-Users
Mean
SD

AAPs Users
Mean
SD

p-value

234
645
41
920

1,362
3,135
87
3,475

408
867
196
1,472

2,142
4,134
198
4,694

<0.0001
0.0242
<0.0001
<0.0001

0.58
0.08
6.79
1.00

1.67
0.31
8.57
1.05

0.97
0.09
21.53
2.41

3.06
0.39
12.59
1.18

<0.0001
0.0925
<0.0001
<0.0001
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Chapter 6: Discussion
This chapter discusses the results of the Medicare study and describes the strengths and limitations
of the study.

6.1 Specific Aim II
The sample used in the analysis was Medicare beneficiaries prescribed AAPs in 2008, 2009
and 2010. Approximately 3.2% of the Medicare beneficiaries were prescribed AAPs each year and
the prevalence remained constant across the three years. The typical AAPs users were 64-year-old
white females, almost half of them had disability and less than 1% had ESRD. Even though the
socio-demographic characteristics are similar to published literature in the same population
(Driessen et al., 2016) the prevalence of AAPs use in this population (3.2%) is lower than in the
published literature (8%), probably because our study used a more conservative definition of AAPs
user. We defined a user as a beneficiary who had at least two claims within 60 days for one AAPs
agent while Driessen et al. defined it as a beneficiary with one AAPs claim. Majority of the AAPs
users were prescribed quetiapine (43%) followed by risperidone (34%) while ziprasidone was the
least commonly prescribed AAPs (7%).
The prevalence of off-label use among AAPs users has been persistent across 2008 to 2010.
The prevalence was 36.7% in 2008 and 36.5% in 2010. The rate of off-label use is lower than that
reported by Driessen et al. in a Medicare population, but our study used the more conservative
definition of AAPs use. Driessen et al. reported a decline in off-label use from 51% to 45% from
2008 to 2010. The typical off-label AAPs user was a 70-year-old white female without a disability
while the typical on-label AAPs user was 60-year-old white female with disability and the sociodemographic factors are in accordance to published results (Driessen et al., 2016). Driessen et al.
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also reported off-label users to be older (mean age = 66 years) compared to on-label users (mean
age = 52 years) and were typically white females.
The prevalence of off-label use among 18-64 year old AAPs users is 24% which is almost
comparable to the 19.5% prevalence of off-label use in a similar age group reported by Citrome et
al. (2013). The prevalence of off-label use among AAPs users greater than 65 years was 49%, this
is lower than the estimates reported by Kamble et al. (86%) and Levinson (83%) in nursing home
residents (Kamble et al., 2010; Levinson, 2011). The difference in the findings between our study
and earlier reports within the same age groups could be explained due to the differences in the
health of the population included in the studies. Our study focused on community dwelling
Medicare beneficiaries whereas the previous studies reported off-label use in Medicare
beneficiaries residing in nursing homes. A majority of these patients were diagnosed with dementia
requiring constant care and this could explain the higher rates of off-label use.
Even though the prevalence of off-label use has not dramatically shifted over the three
years, there have been noticeable changes in the prevalence of the mental health conditions
associated with off-label use. In 2008, 31% of the off-label users had dementia or related other
organic psychosis: this decreased to 24.8% by 2010. Similarly, beneficiaries with depression
decreased from 53.8% to 48.6% and beneficiaries with neurotic and anxiety disorders decreased
slightly from 35.9% to 32.8%. These changes could be reflective of published literature in 2007
by AHRQ on the evidence for safety and efficacy of off-label AAPs use (AHRQ, 2007). Despite
the FDA black box warning due to safety issues and only moderate to low evidence for its efficacy
in dementia (Schneider et al., 2006); it continues to be one of the top three reasons for off-label
use. Similarly, for patients with SSRI resistant depression, there was only modest evidence to
support augmentation of antidepressant therapy with AAPs which could be driving the slight
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decrease in patients with depression. The updated AHRQ review in 2011 states that there may be
new evidence to show that AAPs have efficacy as augmentation therapy in depression and
quetiapine may even be effective as monotherapy (Maglione et al., 2011) which could lead to
differences in prescribing patterns compared to results observed in this study.
Although off-label prescribing is a prevalent and common practice, it is particularly
prevalent in the AAPs class of drugs. Our study found that 37% of AAPs use is in the complete
absence of an FDA approved indication; that is a lower estimate than previously published. This
could be due to federal steps such as the black box warning and the litigations. Even though this
estimate is lower than expected, it is still of concern due to the presence of risk of adverse events
and lack of evidence of effectiveness. Often physicians are faced with no other choice than to
prescribe AAPs due to the patient’s perceived need for treatment and in the face of treatment
resistant patients. It also poses a dilemma to the payers since they have to balance the needs of the
prescriber and patients, with safety concerns and cost issues. It may be worthwhile to educate
patients and physicians in order to change their beliefs about the efficacy of AAPs in off-label
treatment. Patients may also need to be educated about expected signs and symptoms of certain
conditions such as neuropsychiatric symptoms of dementia to help them differentiate abnormal
versus expected symptoms. Educating patients about what is expected could better help them
prepare for these conditions rather than resorting to pharmacotherapy at the onset.
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6.2 Specific Aim III

The purpose of this aim was to compare health care RU and costs between off-label AAPs
users and non-users with mental health diagnoses in a Medicare population. The study results
found that AAPs users were more likely than non-users to use an outpatient facility for mental
health visits. AAPs users were also more likely to have mental health medications and claims.
Total mental health costs were significantly higher among AAPs users ($1,545) in the 12-month
follow up as compared to non-users ($1,057). Medicare paid an additional $396 per beneficiary
per year for mental health costs for off-label users. These findings are similar to the study by Del
Paggio et al.which reported an increase in mental health medication and outpatient costs after
initiation with olanzapine but also reported a decrease in inpatient and emergency costs (Del
Paggio et al., 2002). This difference from our study could be due to the indigent population in the
Del Paggio study who had to be severely and persistently ill to qualify for the publicly funded
program whereas our study population was community dwelling patients.
Upon examining all-cause RU and costs, AAPs users had a significantly lower number of
inpatient visits and costs. AAPs users had 34% lower odds of having an inpatient visit in
comparison to non-users and AAPs non-users incurred an incremental cost of $2,104 per
beneficiary per year for inpatient visits. These findings are similar to the results reported by AlZakwani et al. using data from a private health plan which reported that AAPs users had fewer
inpatient admissions after initiation of AAPs as compared to baseline (Al-Zakwani et al., 2003).
Al-Zakwani et al. reported lower outpatient visits in their population but our study failed
to show a difference in the number of outpatient visits and costs between AAPs users and nonusers. This could be reflective of the different population in the two studies. Our study focused on
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a Medicare population that comprised mostly an older population with mean age of 66 years who
may have scheduled more outpatient visits for increased monitoring of drug effects and chronic
condition treatment but the population in the study was a young cohort form a private health plan.
The different reimbursement policies between private plans and Medicare could also affect these
differences.
Our results also indicate that the rate of RU is sensitive to whether the AAPs is newly
initiated or not. Upon examining RU in off-label AAPs users who had newly initiated the AAPs
in 2009, AAPs users had significantly higher outpatient costs compared to non-users which was
similar to the results we obtained in the MEPS study which concluded that AAPs users had higher
outpatient costs. Inpatient costs had also gone from being higher among non-users to being not
different from AAPs users. These results indicate that in new AAPs users, RU is higher among
users as compared to non-users.
The Del Paggio et al. study is the only one that assessed mental health prescription costs
and our study reflected similar results costs (Del Paggio et al., 2002). Prescription costs were
significantly higher among AAPs users than non-users irrespective of whether they were all-cause
or mental health. AAPs are generally an expensive class of medications and the average cost of
some of the AAPs can be a financial burden on patients. Additionally, during the study period
from 2008-2010 all of the AAPs of interest were available only as brand name products except
risperidone which became available as generic during the study period. Since some of these agents
are now available as generic, AAPs costs may show a downward trend in the future. Prescription
costs can be a financial burden on both Medicare and on beneficiaries. Among AAPs users the
highest share of costs for Medicare (average $4,855 per person per year) and beneficiaries (average
$1,066 per person per year) was attributed to prescription costs. The additional prescription costs
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can be considered cost-effective if treatment with AAPs adequately decreases other health care
costs such as inpatient and emergency costs or if they are clinically effective. In this study,
inpatient costs were found to be the major contributing factor towards total costs among non-users
and a smaller component of total costs in AAPs users. This seems to indicate an association
between AAPs use and lower inpatient costs.

6.3 Specific Aim IV
The objective of this aim was to compare RU and costs associated with Medicare
beneficiaries who are using AAPs for on-label treatment of schizophrenia and bipolar disorder to
non-users with the same indications. The study results show AAPs users to have significantly
higher mental health inpatient, prescription and total costs in comparison to their AAPs non-user
counterparts. There was an additional cost of $718 per beneficiary for total mental health costs and
Medicare spent three times the amount on a beneficiary using AAPs than a non-user during the
follow up period. AAPs users also had significantly higher mental health RU. The odds of having
at least one mental health outpatient and inpatient visit were 68% and 175% higher for AAPs users
than non-users. Revicki et al. reported higher mental health outpatient costs among AAPs users in
a bipolar population and He et al. reported higher number of psychiatric outpatient visits among
AAPs users in a schizophrenic population, which are similar trends to our study results (Revicki
et al., 2003, He et al., 2015).
Prescription costs continue to be the major factor driving total costs among users. It was
the main cost component among on-label AAPs users during the follow-up period while inpatient
costs are the main component among non-users. AAPs users had higher all-cause and mental health
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prescription costs which was similar to the findings by He et al. (He et al., 2015). He et al. reported
AAPs users had a mean cost of $438 per beneficiary which is slightly higher than our findings of
$356 per beneficiary. Inpatient costs follow a different pattern from what is reported by Guo et al.
(Guo et al., 2007). Our study findings show all-cause inpatient costs to be significantly lower
among AAPs users compared to non-users. This finding was robust even after accounting for
skewed distribution or exceptionally high inpatient costs for a few beneficiaries. Guo et al. reported
that AAPs users had higher inpatient and emergency costs but their comparison group was
beneficiaries using mood stabilizers for the treatment of bipolar disorder unlike our comparison
group that included beneficiaries who may have had non-antipsychotic treatment but also includes
those with no treatment at all.
An interesting pattern also exists among the mental health costs between off-label and onlabel AAPs user cohort from Specific Aim III and IV. Off-label users had comparatively higher
inpatient, outpatient and total costs even though both cohorts were using AAPs to treat mental
health conditions. The major difference between the treatments in the two groups is the level of
evidence. While on-label use is supported in literature by strong to moderate evidence, most offlabel use only has moderate to low evidence (Maglione et al., 2011). This could be further reason
to believe that off-label use of AAPs in the treatment of mental health conditions that is not
supported by evidence does not benefit the health care system from a payer perspective because
of increased RU and from a patient perspective since they are exposed to the adverse effects of
these agents. Therefore, the benefit of initiating these agents for off-label treatment should be
weighed against the risks and should be reserved only if no other options are viable.
The typical off-label user is a 66-year-old white female in contrast to a typical on-label
user who is a 52-year-old white male. It is an interesting phenomenon that older patients are more
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likely to be prescribed AAPs in the absence of an FDA approved indication and without strong
clinical evidence to support the use. This is of concern since elderly patients are more susceptible
to the adverse effects of these agents. Off-label AAPs users also had higher number of comorbid
conditions as seen by an average CCI of 0.9 whereas the CCI is only 0.32 among on-label users
which could also explain the higher health care costs among off-label users. Off-label users also
have higher medication burden with an average of 13 medications per beneficiary in comparison
to the 7 medications per on-label user.

6.4 Specific Aim V
In this aim the RU and costs of AAPs users treated for specific mental health conditions
were compared to their non-user counterparts.
Depression: Among patients with depression, the mean number of all-cause inpatient visits
and costs were significantly lower in AAPs users than non-users. The higher prescription costs
among users were offset by their lower inpatient costs leading to a significantly lower total health
care costs. Interestingly both users and non-users had similar medication burden of approximately
13 medications per beneficiary but users had significantly higher costs compared to non-users.
AAPs are increasingly used to treat patients with depression over the years especially with some
of AAPs receiving FDA approval for the same. There is moderate evidence to support the use of
aripiprazole, quetiapine and risperidone as augmentation therapy and quetiapine as monotherapy
therefore treatment with these agents should only be considered in anti-depressant treatment
resistant patients (Maglione et al., 2011).
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Anxiety and neurotic disorder: In patients with anxiety, neurotic and other somatoform
disorders AAPs users had numerically lower inpatient and outpatient costs but it did not achieve
significance. Due to the significantly large prescription costs, total health care costs were
significantly higher in AAPs users compared to non-users. This pattern could be of key interest to
payers such as Medicare and private health plans since they have to incur additional costs on AAPs
users but it could potentially increase the patients’ quality of life and decrease downstream costs
if they are able to avoid multiple inpatient and outpatient visits. The presence of moderate to strong
evidence for the use of risperidone and quetiapine in OCD and anxiety respectively, warrants the
consideration of use of AAPs in this population. Even though use of AAPs in this cohort is offlabel, it could be cost-effective to treat these patients with AAPs if the excess prescription costs
are accompanied by positive clinical changes. Due to the nature of our data, we were unable to
capture clinical effectiveness in our study but future research can focus on examining the relation
between costs and clinical effectiveness.
Dementia: Off-label use of AAPs in elderly patients with dementia is controversial due to
the increased risk of mortality. Despite significantly higher prescription costs in AAPs users, nonusers had higher total costs ($18,803 vs $16,873) than users. Even though this failed to show any
statistical significance, non-users incurred approximately $2,000 additional per person not treated
with AAPs. This might reflect the severity of patients with no other treatment options. There could
be non-users who are severely ill but not prescribed medications due to the risk profile or lack of
evidence of efficacy and who seek emergent or inpatient care for their medication needs. Strong
evidence for the efficacy of AAPs in the treatment of behavioral symptoms of dementia might
explain the practice of prescribing AAPs to patients with dementia despite the associated risks
(Maglione et al., 2011). Therefore, it is once again imperative to consider not only the costs
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associated with AAPs user but also clinical changes in the patients. Patients who have no other
treatment options may very well respond to AAPs under careful monitoring and supervision of
practitioners. Schizophrenia: Patients with schizophrenia using AAPs had significantly higher
prescription and total costs compared to patients not treated with AAPs. AAPs are the first line of
treatment for patients with schizophrenia and all the agents have been FDA approved for this
indication. Since there are no other treatment options, the higher costs of the drugs can still be
cost-effective as patients achieve clinical stability.
Bipolar disorder: Beneficiaries with bipolar disorder showed very similar trends wherein
AAPs users had higher prescription and total costs compared to non-users but no differences were
observed in outpatient and inpatient costs. Guo et al. (2007) discussed in their study about how
despite sufficient evidence to support the use of AAPs in bipolar patients it might be worthwhile
to consider initiating other therapies such as mood stabilizers which are associated with lower RU
and costs. Since our study did not show either cohort to have significantly higher inpatient or
outpatient costs, but showed significantly higher prescription costs, it may be of economic value
to consider other pharmacotherapy which are shown to be equally effective but cheaper in this
population.
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6.5 Strengths and Limitations
To the best of our knowledge, this is the first study that has evaluated RU and costs
associated with off-label use of AAPs in a Medicare population. Published literature has primarily
studied the effects on a younger population even though there is evidence of adverse effects of
AAPs in the elderly population. Further, ours is the first study to use Medicare claims data, which
is a public payer, to evaluate off-label use. Studies have mostly evaluated costs from a private
payer perspective and this study provides estimates of RU and costs from the perspective of a
public payer. In addition, recall and self-report bias was reduced since administrative claims data
was used instead of other sources like self-reported surveys.
The study also used sound methodologic design to control for observed variables. We
identified a control group and used propensity score matching to balance covariates across the
study groups. This reduced the potential for bias. In groups where propensity score matching did
not balance all covariates between the two groups, generalized linear models were used to control
for any unbalanced covariate. Having three years of data also enabled a longer duration of baseline
and follow-up (12 months). The study also used conservative methods when possible to capture
the true effects. For example, to be diagnosed with a medical condition, the beneficiary had to have
two outpatient claims instead of just one claim. Similarly, to be defined as AAPs user, the
beneficiary had to have at least two claims one to 60 days apart for the same antipsychotic.
The study, however, has several limitations. First, the secondary nature of the dataset
imposes certain assumptions. We assume that patients with claims for AAPs are taking the
medication as prescribed. We also assume that the information recorded in the claims dataset is
accurate. Databases may be subject to miscoding which could lead to inaccurate and biased results.
There may also be underrepresentation of certain diagnoses since diseases with greater severity
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could be listed under primary diagnosis (Brookhart, 2014). For example, a patient’s primary
diagnosis code reports myocardial infarction but his depression diagnosis is not coded. Second,
we cannot determine which medical condition the prescribed drug is treating. Therefore, we were
unable to determine if AAPs were used in off-label or on-label treatment in beneficiaries with
multiple mental health conditions. We addressed this limitation by creating mutually exclusive
groups of beneficiaries who were using AAPs for off-label treatment or on-label treatment by
excluding those beneficiaries who had indications for both an off-label and on-label condition. By
creating mutually exclusive groups, we ascertain that the users are using the drug only in the
presence of the particular condition even if we cannot ascertain that the drug was used for that
condition. In the final Specific Aim we also created mutually exclusive groups by specific disease
state to identify beneficiaries who were using AAPs only in the presence of diagnosis claims for
depression, anxiety, schizophrenia or bipolar disorder. Third, even though matching was
performed to remove differences among the groups due to observed variables, the study was not
able to control for unobserved differences such as patient specific factors including patient
preferences. These predictors could have influenced the choice of AAPs in the treatment of certain
conditions and could be potentially influencing the results. For example, patients intolerable to
adverse effects of antidepressants such as decreased libido and disturbed sleep cycles may prefer
initiation of AAPs. Fourth, since we used claims data and not electronic health records we were
unable to obtain past medical history, which can influence RU and costs. We tried to address this
limitation by using 12 months of baseline period to capture comorbid conditions using claims data.
Even though we addressed this limitation in the best possible manner using claims data, we have
to recognize that only conditions for which the patient had an inpatient or outpatient visit was
captured in their baseline. Therefore, any conditions for which the beneficiary did not seek

122

treatment during the study period were not captured. Fifth, even though we tried to control for
severity of disease by including the baseline RU in the propensity model, there may still be
underlying differences among the AAPs users and non-users due to the level of severity of disease
which is beyond the researcher’s control. Sixth, due to limited funding the study was limited to
institutional costs which were obtained from inpatient, outpatient and prescription costs. We did
not include the carrier file claims in this study therefore the RU and costs estimated in this study
do not reflect physician office-based outpatient costs. Similarly, other costs, which may be
estimated from other Medicare files such as home health and hospice, were also not included in
this study. Due to the lack of these components, we were unable to estimate the total RU associated
with off-label use and the study focused only on institutional costs. Additionally, since we did not
have the carrier file, we were restricted to identifying chronic health and other mental conditions
by only using inpatient and institutional outpatient claims. In order to restrict this limitation, we
used the Chronic Conditions and Other Chronic Conditions files to identify diagnoses codes that
may not have appeared in the claims during the 3-year study period.
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6.6 Conclusions and Future Research
Off-label use of AAPs is an important public health issue that has gained attention the last
few years. As a class of drugs, AAPs carry their own adverse risk profile even as they are used to
treat mental health conditions for which no other treatments exist or to treat patients who have
become resistant to other treatments. To the best of our knowledge no other study has examined
the RU and costs in off-label AAPs users using nationally representative data or Medicare data.
The objective of the pilot study was to examine patterns of RU among off-label AAPs users
in a nationally representative population. Patients using AAPs for off-label treatment of mental
health conditions had higher all-cause utilization of any resource, office-based provider visits, and
hospital inpatient visits per year compared to those not using AAPs in off-label treatment and their
total costs including prescription and office-based outpatient costs were significantly higher.
The objective of the second study was to evaluate the prevalence of off-label use in
Medicare beneficiaries and to compare RU between off-label AAPs users and non-users. Of the
total beneficiaries, 3.2% used AAPs and 36% of these were off-label users. Some of the most
common indications of off-label use were depression, anxiety and dementia. Total mental health
costs, outpatient costs and medication costs were higher among off-label AAPs users but all-cause
inpatient costs were higher among non-users.
Off-label prescribing of AAPs continued to be a prevalent practice though it affects less
than half of all AAPs users. For all-cause RU and costs, we had different results from the MEPS
study and the Medicare study: among MEPS respondents AAPs users had higher RU and costs but
Medicare AAPs users had lower RU and costs. This difference in results could be due to the
difference in the population (younger vs. older), design (cross-sectional vs. cohort), study methods
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(regression vs. matching), or data (self-report vs. administrative claims). Medicare study also
showed that AAPs users had higher RU and costs associated with mental health visits and
prescription cost was the main factor driving total costs. This study points to some association
towards AAPs use and increased costs. If the increased costs from medications can be offset by
decreased inpatient or outpatient costs or is accompanied with clinical effectiveness then off-label
treatment with AAPs can be recommended as a cost-effective option.
Future research should examine the RU patterns based on the evidence supporting the offlabel treatment. Cohorts of patients with off-label but supported use and off-label but unsupported
use should be identified and compared. Future research should also focus on examining the
association between RU and clinical outcomes. For example, does off-label use of AAPs improve
clinical outcomes and improve quality of life despite the higher RU? This would help identify costeffectiveness of using AAPs for off-label use. Future researchers can also assess the effects of
duration of therapy and adherence on long term RU and costs.
As we move forward, it will be interesting to observe the RU pattern in this population in
the after-effects of the CMS partnerships. The results of this study will serve as the baseline as we
try to identify if utilization and costs have increased or decreased as a direct effect of these changes.

125

References
ADA, APA, AACE, & NAASO. (2004). Consensus development conference on antipsychotic
drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601.

Ahearn, E. P., Krohn, A., Connor, K. M., & Davidson, J. R. (2003). Pharmacologic treatment of
posttraumatic stress disorder: A focus on antipsychotic use. Annals of Clinical Psychiatry :
Official Journal of the American Academy of Clinical Psychiatrists, 15(3-4), 193-201.

Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011).
Increasing off-label use of antipsychotic medications in the united states, 19952008. Pharmacoepidemiology and Drug Safety, 20(2), 177-184. doi:10.1002/pds.2082 [doi]

Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., et al.
(1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. The
American Journal of Psychiatry, 156(11), 1686-1696. doi:10.1176/ajp.156.11.1686 [doi]

American Psychiatric Association: Practice guidelines for the treatment of patients with acute
stress disorder and post-traumatic stress disorder. Am J Psychiatry (2009).
American Psychiatric Association: Practice guidelines for the treatment of patients with major
depressive disorder 3 rd edition. Am J Psychiatry (2010).
American Psychiatric Association: Practice guidelines for the treatment of patients with
Alzheimer’s and other dementias. Am J Psychiatry (2014).

126

Bagnall, A., Lewis, R. A., & Leitner, M. L. (2000). Ziprasidone for schizophrenia and severe
mental illness. The Cochrane Database of Systematic Reviews, (4)(4), CD001945.
doi:CD001945 [pii]

Bauer, M. S., Lee, A., Li, M., Bajor, L., Rasmusson, A., & Kazis, L. E. (2014). Off-label use of
second generation antipsychotics for post-traumatic stress disorder in the department of
veterans affairs: Time trends and sociodemographic, comorbidity, and regional
correlates. Pharmacoepidemiology and Drug Safety, 23(1), 77-86. doi:10.1002/pds.3507
[doi]

Bernardy, N. C., Lund, B. C., Alexander, B., & Friedman, M. J. (2012). Prescribing trends in
veterans with posttraumatic stress disorder. The Journal of Clinical Psychiatry, 73(3), 297303. doi:10.4088/JCP.11m07311 [doi]

Blanchette, C. M., Craver, C., Belk, K. W., Lubeck, D. P., Rossetti, S., & Gutierrez, B. (2015).
Hospital-based inpatient resource utilization associated with autosomal dominant polycystic
kidney disease in the US. Journal of Medical Economics, 18(4), 303-311.
doi:10.3111/13696998.2014.985381 [doi]

Briggs, A. (1999). Economics notes: Handling uncertainty in economic evaluation. BMJ
(Clinical Research Ed.), 319(7202), 120.

Brodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., et al. (2003). A
randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation,
and psychosis of dementia. The Journal of Clinical Psychiatry, 64(2), 134-143.

127

Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of
classifying prognostic comorbidity in longitudinal studies: Development and
validation. Journal of Chronic Diseases, 40(5), 373-383.

Chen, W., Deveaugh-Geiss, A. M., Palmer, L., Princic, N., & Chen, Y. T. (2013). Patterns of
atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. Human
Psychopharmacology, 28(5), 428-437. doi:10.1002/hup.2326 [doi]

Citrome, L., Kalsekar, I., Guo, Z., Laubmeier, K., & Hebden, T. (2013). Diagnoses associated
with use of atypical antipsychotics in a commercial health plan: A claims database
analysis. Clinical Therapeutics, 35(12), 1867-1875. doi:10.1016/j.clinthera.2013.09.006
[doi]

Comer, J. S., Mojtabai, R., & Olfson, M. (2011). National trends in the antipsychotic treatment
of psychiatric outpatients with anxiety disorders. The American Journal of
Psychiatry, 168(10), 1057-1065. doi:10.1176/appi.ajp.2011.11010087 [doi]

Crivera, C., DeSouza, C., Kozma, C. M., Dirani, R. D., Mao, L., & Macfadden, W. (2011).
Resource utilization in patients with schizophrenia who initiated risperidone long-acting
therapy: Results from the schizophrenia outcomes utilization relapse and clinical evaluation
(SOURCE). BMC Psychiatry, 11, 168-244X-11-168. doi:10.1186/1471-244X-11-168 [doi]

Consumer Price Index. Bureau of Labor Statistics 2016; Available at: URL:
http://www.bls.gov/cpi/cpi_dr.htm. Accessed August 10, 2016.

128

Dagher, R. K., Chen, J., & Thomas, S. B. (2015). Gender differences in mental health outcomes
before, during, and after the great recession. PloS One, 10(5), e0124103.
doi:10.1371/journal.pone.0124103 [doi]

Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of secondgeneration antipsychotics. Archives of General Psychiatry, 60(6), 553-564.
doi:10.1001/archpsyc.60.6.553 [doi]

Deberdt, W. G., Dysken, M. W., Rappaport, S. A., Feldman, P. D., Young, C. A., Hay, D. P., et
al. (2005). Comparison of olanzapine and risperidone in the treatment of psychosis and
associated behavioral disturbances in patients with dementia. The American Journal of
Geriatric Psychiatry : Official Journal of the American Association for Geriatric
Psychiatry, 13(8), 722-730. doi:13/8/722 [pii]

Deyo, R. A., Cherkin, D. C., & Ciol, M. A. (1992). Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. Journal of Clinical Epidemiology, 45(6), 613619. doi:0895-4356(92)90133-8 [pii]

Dickson, R. A., Dalby, J. T., Addington, D., Williams, R., & McDougall, G. M. (1999). Hospital
days in risperidone-treated patients. Canadian Journal of Psychiatry.Revue Canadienne De
Psychiatrie, 44(9), 909-913.

Domino, M. E., & Swartz, M. S. (2008). Who are the new users of antipsychotic
medications? Psychiatric Services (Washington, D.C.), 59(5), 507-514.
doi:10.1176/appi.ps.59.5.507 [doi]

129

Dore, D. D., Trivedi, A. N., Mor, V., Friedman, J. H., & Lapane, K. L. (2009). Atypical
antipsychotic use and risk of fracture in persons with parkinsonism. Movement Disorders :
Official Journal of the Movement Disorder Society,24(13), 1941-1948.
doi:10.1002/mds.22679 [doi]

Douglas, I. J., & Smeeth, L. (2008). Exposure to antipsychotics and risk of stroke: Self
controlled case series study. BMJ (Clinical Research Ed.), 337, a1227.
doi:10.1136/bmj.a1227 [doi]

Driessen, J., Baik, S. H., & Zhang, Y. (2016). Trends in off-label use of second-generation
antipsychotics in the medicare population from 2006 to 2012. Psychiatric Services
(Washington, D.C.), 67(8), 898-903. doi:10.1176/appi.ps.201500316 [doi]

Duggan, L., Fenton, M., Dardennes, R. M., El-Dosoky, A., & Indran, S. (2003). Olanzapine for
schizophrenia. The Cochrane Database of Systematic Reviews, (1)(1), CD001359.
doi:10.1002/14651858.CD001359 [doi]

El-Sayeh, H. G., & Morganti, C. (2006). Aripiprazole for schizophrenia. The Cochrane Database
of Systematic Reviews, (2)(2), CD004578. doi:10.1002/14651858.CD004578.pub3 [doi]

Erzegovesi, S., Cavallini, M. C., Cavedini, P., Diaferia, G., Locatelli, M., & Bellodi, L. (2001).
Clinical predictors of drug response in obsessive-compulsive disorder. Journal of Clinical
Psychopharmacology, 21(5), 488-492.

Ettner, S. L. (1998). Inpatient psychiatric care of medicare beneficiaries with state buy-in
coverage. Health Care Financing Review, 20(2), 55-69.

130

Field, R. I. (2010). Antipsychotic medications are spelling legal trouble for drugmakers. P & T :
A Peer-Reviewed Journal for Formulary Management, 35(11), 621-622.

Gareri, P., Segura-Garcia, C., Manfredi, V. G., Bruni, A., Ciambrone, P., Cerminara, G., et al.
(2014). Use of atypical antipsychotics in the elderly: A clinical review. Clinical
Interventions in Aging, 9, 1363-1373. doi:10.2147/CIA.S63942 [doi]

Gerhard, T., Akincigil, A., Correll, C. U., Foglio, N. J., Crystal, S., & Olfson, M. (2014).
National trends in second-generation antipsychotic augmentation for nonpsychotic
depression. The Journal of Clinical Psychiatry, 75(5), 490-497. doi:10.4088/JCP.13m08675
[doi]

Gill, S. S., Rochon, P. A., Herrmann, N., Lee, P. E., Sykora, K., Gunraj, N., et al. (2005).
Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective
cohort study. BMJ (Clinical Research Ed.),330(7489), 445. doi:bmj.38330.470486.8F [pii]

Ginsberg, G., Lerner, Y., Mark, M., & Popper, M. (1997). Prior hospitalization and age as
predictors of mental health resource utilization in israel. Social Science & Medicine
(1982), 44(5), 623-633. doi:S0277953696002146 [pii]

Glassman, A. H., & Bigger, J. T.,Jr. (2001). Antipsychotic drugs: Prolonged QTc interval,
torsade de pointes, and sudden death. The American Journal of Psychiatry, 158(11), 17741782. doi:10.1176/appi.ajp.158.11.1774 [doi]

Guo, J. J., Keck, P. E.,Jr, Li, H., Jang, R., & Kelton, C. M. (2008). Treatment costs and health
care utilization for patients with bipolar disorder in a large managed care population. Value

131

in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes
Research, 11(3), 416-423. doi:10.1111/j.1524-4733.2007.00287.x [doi]

Harrison, J. N., Cluxton-Keller, F., & Gross, D. (2012). Antipsychotic medication prescribing
trends in children and adolescents. Journal of Pediatric Health Care : Official Publication
of National Association of Pediatric Nurse Associates & Practitioners, 26(2), 139-145.
doi:10.1016/j.pedhc.2011.10.009 [doi]

He, X., Wu, J., Jiang, Y., Liu, L., Ye, W., Xue, H., et al. (2015). Health care resource utilization
and direct medical costs for patients with schizophrenia initiating treatment with atypical
versus typical antipsychotics in tianjin, china. BMC Health Services Research, 15, 149-0150819-y. doi:10.1186/s12913-015-0819-y [doi]

Herrmann, N., & Lanctot, K. L. (2005). Do atypical antipsychotics cause stroke? CNS
Drugs, 19(2), 91-103. doi:1921 [pii]

Hunter, R. H., Joy, C. B., Kennedy, E., Gilbody, S. M., & Song, F. (2003). Risperidone versus
typical antipsychotic medication for schizophrenia. The Cochrane Database of Systematic
Reviews, (2)(2), CD000440. doi:10.1002/14651858.CD000440 [doi]

Hwang, Y. J., Dixon, S. N., Reiss, J. P., Wald, R., Parikh, C. R., Gandhi, S., et al. (2014).
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse
outcomes in older adults: A population-based cohort study. Annals of Internal
Medicine, 161(4), 242-248. doi:10.7326/M13-2796 [doi]

132

Kales, H. C., Valenstein, M., Kim, H. M., McCarthy, J. F., Ganoczy, D., Cunningham, F., et al.
(2007). Mortality risk in patients with dementia treated with antipsychotics versus other
psychiatric medications. The American Journal of Psychiatry, 164(10), 1568-76; quiz 1623.
doi:164/10/1568 [pii]

Kales, H. C., Zivin, K., Kim, H. M., Valenstein, M., Chiang, C., Ignacio, R. V., et al. (2011).
Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry, 68(2),
190-197. doi:10.1001/archgenpsychiatry.2010.200 [doi]

Kamble, P., Sherer, J., Chen, H., & Aparasu, R. (2010). Off-label use of second-generation
antipsychotic agents among elderly nursing home residents. Psychiatric Services
(Washington, D.C.), 61(2), 130-136. doi:10.1176/appi.ps.61.2.130 [doi]

Kawatkar, A. A., Knight, T. K., Moss, R. A., Sikirica, V., Chu, L. H., Hodgkins, P., et al. (2014).
Impact of mental health comorbidities on health care utilization and expenditure in a large
US managed care adult population with ADHD. Value in Health : The Journal of the
International Society for Pharmacoeconomics and Outcomes Research, 17(6), 661-668.
doi:10.1016/j.jval.2014.06.002 [doi]

Khan, S. S., Kazmi, W. H., Abichandani, R., Tighiouart, H., Pereira, B. J., & Kausz, A. T.
(2002). Health care utilization among patients with chronic kidney disease. Kidney
International, 62(1), 229-236. doi:S0085-2538(15)48540-0 [pii]

Kuehn, B. M. (2010). Questionable antipsychotic prescribing remains common, despite serious
risks. Jama, 303(16), 1582-1584. doi:10.1001/jama.2010.453 [doi]

133

Lage, M. J., & Rajagopalan, K. (2006). Hospitalization and emergency department visits among
patients treated with atypical antipsychotics:Evidence from a commercially insured
population. The Journal of Applied Research,6(2), 115-125.

Leal, A., Rosillon, D., Mehnert, A., Jarema, M., & Remington, G. (2004). Healthcare resource
utilization during 1-year treatment with long-acting, injectable
risperidone. Pharmacoepidemiology and Drug Safety, 13(11), 811-816. doi:10.1002/pds.978
[doi]

Lepine, B. A., Moreno, R. A., Campos, R. N., & Couttolenc, B. F. (2012). Treatment-resistant
depression increases health costs and resource utilization. Revista Brasileira De Psiquiatria
(Sao Paulo, Brazil : 1999), 34(4), 379-388. doi:S1516-44462012000400004 [pii]

Leslie, D. L., Mohamed, S., & Rosenheck, R. A. (2009). Off-label use of antipsychotic
medications in the department of veterans affairs health care system. Psychiatric Services
(Washington, D.C.), 60(9), 1175-1181. doi:10.1176/appi.ps.60.9.1175 [doi]

Leslie, D. L., & Rosenheck, R. A. (2004). Incidence of newly diagnosed diabetes attributable to
atypical antipsychotic medications. The American Journal of Psychiatry, 161(9), 17091711. doi:10.1176/appi.ajp.161.9.1709 [doi]

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O.,
et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic
schizophrenia. The New England Journal of Medicine,353(12), 1209-1223.
doi:NEJMoa051688 [pii]

134

Linden, M., & Thiels, C. (2001). Epidemiology of prescriptions for neuroleptic drugs:
Tranquilizers rather than antipsychotics. Pharmacopsychiatry, 34(4), 150-154.
doi:10.1055/s-2001-15880 [doi]

Lindenmayer, J. P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., et al.
(2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with
typical or atypical antipsychotics. The American Journal of Psychiatry, 160(2), 290-296.
doi:10.1176/appi.ajp.160.2.290 [doi]

Liperoti, R., Gambassi, G., Lapane, K. L., Chiang, C., Pedone, C., Mor, V., et al. (2005).
Cerebrovascular events among elderly nursing home patients treated with conventional or
atypical antipsychotics. The Journal of Clinical Psychiatry, 66(9), 1090-1096.

Lopez, O. L., Becker, J. T., Sweet, R. A., Klunk, W., Kaufer, D. I., Saxton, J., et al. (2003).
Patterns of change in the treatment of psychiatric symptoms in patients with probable
alzheimer's disease from 1983 to 2000. The Journal of Neuropsychiatry and Clinical
Neurosciences, 15(1), 67-73. doi:10.1176/jnp.15.1.67 [doi]

Lorenz, R. A., Jackson, C. W., & Saitz, M. (2010). Adjunctive use of atypical antipsychotics for
treatment-resistant generalized anxiety disorder. Pharmacotherapy, 30(9), 942-951.
doi:10.1592/phco.30.9.942 [doi]

Lucado, J., Paez, K., & Elixhauser, A. (2006). Medication-related adverse outcomes in U.S.
hospitals and emergency departments, 2008: Statistical brief #109. Healthcare cost and
utilization project (HCUP) statistical briefs (). Rockville (MD): doi:NBK54566
[bookaccession]
135

Maglione, M., Maher, A. R., Hu, J., Wang, Z., Shanman, R., Shekelle, P. G., et al. (2011).
doi:NBK66081 [bookaccession]

Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J. H., Ewing, B., et al. (2011). Efficacy
and comparative effectiveness of atypical antipsychotic medications for off-label uses in
adults: A systematic review and meta-analysis. Jama, 306(12), 1359-1369.
doi:10.1001/jama.2011.1360 [doi]

Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J.,
et al. (2007). Risperidone for treatment-refractory major depressive disorder: A randomized
trial. Annals of Internal Medicine,147(9), 593-602. doi:147/9/593 [pii]

Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., et al. (2014).
Clinical pharmacology of atypical antipsychotics: An update. EXCLI Journal, 13, 11631191.

McIntyre, R. S., McCann, S. M., & Kennedy, S. H. (2001). Antipsychotic metabolic effects:
Weight gain, diabetes mellitus, and lipid abnormalities. Canadian Journal of
Psychiatry.Revue Canadienne De Psychiatrie, 46(3), 273-281.

Mort, J. R., Sailor, R., & Hintz, L. (2014). Partnership to decrease antipsychotic medication use
in nursing homes: Impact at the state level. South Dakota Medicine : The Journal of the
South Dakota State Medical Association,67(2), 67-69.

Newcomer, J. W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: A
comprehensive literature review. CNS Drugs, 19 Suppl 1, 1-93.

136

Pariente, A., Fourrier-Reglat, A., Ducruet, T., Farrington, P., Beland, S. G., Dartigues, J. F., et al.
(2012). Antipsychotic use and myocardial infarction in older patients with treated
dementia. Archives of Internal Medicine,172(8), 648-53; discussion 654-5.
doi:10.1001/archinternmed.2012.28 [doi]

Parsons LS. Reducing Bias in a propensity score matched pair sample using greedy matching
techniques. Accessed June 5, 2016.

Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006). Off-label prescribing among officebased physicians. Archives of Internal Medicine, 166(9), 1021-1026. doi:166/9/1021 [pii]

Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., & Maina, G. (1995). Predictors of drug
treatment response in obsessive-compulsive disorder. The Journal of Clinical
Psychiatry, 56(8), 368-373.

Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009). Atypical antipsychotic
drugs and the risk of sudden cardiac death. The New England Journal of Medicine, 360(3),
225-235. doi:10.1056/NEJMoa0806994 [doi]

Reinhold, J. A., & Rickels, K. (2015). Pharmacological treatment for generalized anxiety
disorder in adults: An update. Expert Opinion on Pharmacotherapy, 16(11), 1669-1681.
doi:10.1517/14656566.2015.1059424 [doi]

Revicki, D. A., Paramore, L. C., Sommerville, K. W., Swann, A. C., Zajecka, J. M., & Depakote
Comparator Study Group. (2003). Divalproex sodium versus olanzapine in the treatment of

137

acute mania in bipolar disorder: Health-related quality of life and medical cost
outcomes. The Journal of Clinical Psychiatry, 64(3), 288-294.

Reynolds, G. P., & Kirk, S. L. (2010). Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacology & Therapeutics, 125(1), 169-179.
doi:10.1016/j.pharmthera.2009.10.010 [doi]

Rickels, K., Rynn, M., Iyengar, M., & Duff, D. (2006). Remission of generalized anxiety
disorder: A review of the paroxetine clinical trials database. The Journal of Clinical
Psychiatry, 67(1), 41-47.

Rosenbaum, Paul R., and Donald B. Rubin. 1983. The central role of the propensity score in
observational studies for causal effects. Biometrika 70(1):41-55.

Rosenbluth, M., & Sinyor, M. (2012). Off-label use of atypical antipsychotics in personality
disorders. Expert Opinion on Pharmacotherapy, 13(11), 1575-1585.
doi:10.1517/14656566.2011.608351 [doi]

Sajatovic, M., Vernon, L., & Semple, W. (1997). Clinical characteristics and health resource use
of men and women veterans with serious mental illness. Psychiatric Services (Washington,
D.C.), 48(11), 1461-1463. doi:10.1176/ps.48.11.1461 [doi]

Schneider, L. S., Dagerman, K. S., & Insel, P. (2005). Risk of death with atypical antipsychotic
drug treatment for dementia: Meta-analysis of randomized placebo-controlled
trials. Jama, 294(15), 1934-1943. doi:294/15/1934 [pii]

138

Sheehan, D. V., Keene, M. S., Eaddy, M., Krulewicz, S., Kraus, J. E., & Carpenter, D. J. (2008).
Differences in medication adherence and healthcare resource utilization patterns: Older
versus newer antidepressant agents in patients with depression and/or anxiety
disorders. CNS Drugs, 22(11), 963-973. doi:22115 [pii]

Shin, J. Y., Choi, N. K., Jung, S. Y., Lee, J., Kwon, J. S., & Park, B. J. (2013). Risk of ischemic
stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: A
population-based, case-crossover study. Journal of Psychopharmacology (Oxford,
England), 27(7), 638-644. doi:10.1177/0269881113482530 [doi]

Social Security Administration. SSI annual statistical report, 2011. Obtained September 10,
2016. < https://www.ssa.gov/policy/docs/statcomps/ssi_asr/2011/ssi_asr11.pdf>

Srisurapanont, M., Maneeton, B., & Maneeton, N. (2004). Quetiapine for schizophrenia. The
Cochrane Database of Systematic Reviews, (2)(2), CD000967.
doi:10.1002/14651858.CD000967.pub2 [doi]

Star, K., Bate, A., Meyboom, R. H., & Edwards, I. R. (2010). Pneumonia following
antipsychotic prescriptions in electronic health records: A patient safety concern? The
British Journal of General Practice : The Journal of the Royal College of General
Practitioners, 60(579), e385-94. doi:10.3399/bjgp10X532396 [doi]

Sullivan, G. M., & Feinn, R. (2012). Using effect size-or why the P value is not enough. Journal
of Graduate Medical Education, 4(3), 279-282. doi:10.4300/JGME-D-12-00156.1 [doi]

139

Tabarrok, A. T. (2000). Assessing the FDA via the anamoly of off-label drug prescribing. The
Independent Review, 1(1), 25-53.

Thase, M. E., Howland, R. H., & Friedman, E. S. (1998). Treating antidepressant nonresponders
with augmentation strategies: An overview. The Journal of Clinical Psychiatry, 59 Suppl 5,
5-12; discussion 13-5.

Trifiro, G., Gambassi, G., Sen, E. F., Caputi, A. P., Bagnardi, V., Brea, J., et al. (2010).
Association of community-acquired pneumonia with antipsychotic drug use in elderly
patients: A nested case-control study. Annals of Internal Medicine, 152(7), 418-25, W13940. doi:10.7326/0003-4819-152-7-201004060-00006 [doi]

Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., et al.
(2006). Evaluation of outcomes with citalopram for depression using measurement-based
care in STAR*D: Implications for clinical practice. The American Journal of
Psychiatry, 163(1), 28-40. doi:163/1/28 [pii]

Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M., Fleischhacker, W. W., et al.
(2007). Metabolic side effects of antipsychotic medication. International Journal of Clinical
Practice, 61(8), 1356-1370. doi:IJCP1416 [pii]

Twomey, C. D., Baldwin, D. S., Hopfe, M., & Cieza, A. (2015). A systematic review of the
predictors of health service utilisation by adults with mental disorders in the UK. BMJ
Open, 5(7), e007575-2015-007575. doi:10.1136/bmjopen-2015-007575 [doi]

140

Wooltorton, E. (2002). Risperidone (risperdal): Increased rate of cerebrovascular events in
dementia trials. CMAJ : Canadian Medical Association Journal = Journal De l'Association
Medicale Canadienne, 167(11), 1269-1270.

United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in
the United States. National Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases, Bethesda, MD, 2014.

Wu, C. H., Erickson, S. R., Piette, J. D., & Balkrishnan, R. (2012). Mental health resource
utilization and health care costs associated with race and comorbid anxiety among medicaid
enrollees with major depressive disorder.Journal of the National Medical
Association, 104(1-2), 78-88. doi:S0027-9684(15)30121-8 [pii]

141

